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Obesity and diabetes. 
Most adult animals and humans tend to keep their body weight within a relative 
narrow range, despite large variations in daily food intake and physical activity. This 
indicates that body weight is tightly regulated. However, the growing percentage of 
people that are overweight or obese shows that this regulatory mechanism is not 
flawless. There is considerable evidence that during evolution, this regulation system 
has evolved as a system intended for conservation of energy, seeking food in times 
of famine and storing energy in times of plenty. This increased the survival chance 
during long periods of energy deprivation. There has been little evolutionary pressure 
to increase energy expenditure or reduce food intake once energy stores are replete. 
Therefore, this regulatory system is biased strongly towards weight gain and storage 
of fat, with few mechanisms that encourage weight loss 1.  
Nowadays, in our Western society food is in abundance and energy-rich with 
high levels of sugar and saturated fats. At the same time, large shifts towards less 
physically demanding work have been observed 2. These environmental changes are 
reflected in the percentages of overweight/obese people. The prevalence of 
overweight and obesity is commonly assessed by using body mass index (BMI), 
defined as the weight in kilograms divided by the square of the height in meters 
(kg/m2). A BMI over 25 kg/m2 is defined as overweight and a BMI over 30 kg/m2 as 
obese. Globally, obesity has reached epidemic proportions with more than 1 billion 
overweight adults, at least 300 million of them obese (World Health Organization, 
2003). In The Netherlands, 47% of the adults are overweight with 11% being obese 
(CBS, 2004).  
Overweight and obesity are caused by a disturbed balance between 
energy/food intake and energy expenditure. Overweight and obesity pose a major 
risk for chronic diseases, particularly type 2 diabetes mellitus, cardiovascular 
disease, hypertension, stroke and certain forms of cancer 3. The likelihood of 
developing type 2 diabetes mellitus and hypertension rises steeply with increasing 
body fatness. Approximately 85% of patients with diabetes mellitus have type 2 and 
of these patients, 90% are obese or overweight (WHO, 2003). Type 2 diabetes 
mellitus is no immediate life threatening disease, but the increased glucose levels 
ultimately lead to complications, such as cardiovascular disease, retinopathy, 
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nephropathy and cognitive dysfunction. These complications will reduce the overall 
quality of life, and also form an increased risk of premature death. 
 
Regulation of food intake. 
Hypothalamic regulation of food intake. 
Energy/food intake is regulated by a highly complex system, that integrates several 
signals concerning the metabolic status and energy expenditure, but also the 
availability of food, memory of food and the social situation. This regulatory 
mechanism involves several brain regions ranging from cortex to brainstem, but most 
interest has focused on the hypothalamus, which is considered as the main 
regulatory feeding center of the brain.  
The hypothalamus consists of several nuclei, that are involved in the 
regulation of food intake. One of them is the arcuate nucleus, which lies around the 
base of the third ventricle, immediately above the median eminence. Due to this 
position, the neurons of the arcuate nucleus have easy access to peripheral satiety 
factors. First of all, peripheral signals can gain access to the arcuate nucleus from 
the cerebrospinal fluid (csf) in the third ventricle (either by diffusion or via 
receptors)4;5. Secondly, peripheral signals can easily reach the arcuate axon 
terminals, because the endothelial barrier within the median eminence lacks tight 
junctions 6. Therefore, the blood-brain-barrier is not present in this region and arcuate 
axon terminals are in direct contact with signals from the bloodstream. The neurons 
of the arcuate nucleus are called first order neurons because of this direct contact 
with peripheral satiety factors. The arcuate nucleus contains two distinct groups of 
neurons with opposing effects on food intake (Fig. 1). One group consists of neurons 
that co-express neuropeptide Y (NPY) and agouti-related peptide (AgRP), 
neuropeptides, that activate appetite 7;8. The other group consists of neurons that co-
express pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated 
transcript (CART), both neuropeptides that inhibit appetite 9.  
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Figure 1. Central command centers. 
The arcuate nucleus of the brain 
contains two sets of neurons with 
opposing effects. Activation of the 
NPY/AgRP neurons increases 
appetite, whereas activation of the 
POMC/CART neurons has the 
opposite effect.  
Adapted from Marx J, 2003. Science 







During fasting or a fall in the body’s energy stores, the mRNA expression of 
the two orexigenic peptides, NPY and AgRP, is increased. NPY and AgRP will 
produce a shift towards a positive energy balance by increasing food intake and 
decreasing energy expenditure 10;11. From the two orexigenic neuropeptides, NPY is 
the most potent one. Currently, six different NPY receptors have been identified, that 
mediate the effects of NPY 12;13. Most of the NPY neurons (~90%) also contain AgRP 
8. AgRP acts as a high affinity antagonist of the melanocortin 3 and 4 receptors 
(MC3R and MC4R), 2 receptors downstream of the POMC pathway 14;15. 
Furthermore, NPY/AgRP neurons can inhibit their neighbouring POMC/CART 
neurons by means of the neurotransmitter GABA 16. 
During the fed condition or a state of positive energy balance, the mRNA 
expression of the two anorexigenic neuropeptides, POMC and CART is increased. 
These neuropeptides will produce a shift towards a negative energy balance by 
decreasing food intake and increasing energy expenditure 10;11. POMC is a precursor 
molecule that is cleaved into several peptides that are called melanocortins (MC). Of 
these melanocortins, α-melanocyte-stimulating hormone (α-MSH) is considered to be 
the most important one for regulation of food intake. The effects of melanocortins are 
mediated by melanocortin receptors of which currently five are cloned. Two of them, 
MC3R and MC4R, are mainly expressed within the brain where they interfere with 
food intake. Both receptors have a high affinity for α-MSH, but also for AgRP. CART 
is co-localized with POMC in the arcuate nucleus. However, the mechanisms that 
14
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Figure 2. Appetite conrollers.  
The body produces several hormones that 
act through the brain to regulate short- and 
long-term appetite.  
From Marx J, 2003. Science 299, 846-849. 
Republished with permission. 
 
mediate the effects of CART are still poorly 
understood and until now there has not 
been a receptor identified. 
The neurons from the arcuate 
nucleus project to second order neurons in 
the paraventricular nucleus, ventromedial 
nucleus, dorsomedial hypothalamic nucleus 
and the lateral hypothalamic area 10;11. The 
second order neurons in these areas are 
also divided into neurons that contain 
orexigenic or anorexigenic neuropeptides. 
Second order orexigenic neuropeptides are 
melanin-concentrating hormone (MCH) and 
orexins (or hypocretins), second order 
anorexigenic neuropeptides are 
corticotropin-releasing hormone (CRH) and 
thyrotropin-releasing hormone (TRH). The 
second order neurons project to different 
autonomic centers in the brainstem. In 
these areas satiety signals are processed 
and the hypothalamic signals are integrated 
with afferent information related to satiety 
17. 
The hypothalamic pathways, that regulate food intake are essential for the 
long-term regulation of food intake and energy homeostasis. Apparently, in the obese 
situation these pathways are not functioning properly. Indeed, it has been shown that 
the balance between orexigenic and anorexigenic neuropeptides is profoundly 
altered in several animal models of obesity 18. 
 
Peripheral signals that regulate food intake. 
Numerous peripheral signals act on the central regulatory centers, and, thereby, 
contribute to the regulation of food intake and energy expenditure (Fig. 2). These 
peripheral signals can be divided in long-term and short-term signals 19. Long-term 
signals provide information about body fat stores and the amount of energy 
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consumed over a more prolonged period of time. Short-term signals do not reflect 
body adiposity, but provide information about hunger and satiety.  
Leptin and insulin are examples of long-term signals. Leptin is secreted from 
adipocytes in proportion to the amount of adipose tissue 20. Although insulin is 
secreted from pancreatic ß–cells, the circulating concentrations of insulin are also 
proportional to adipose tissue 21. However, the overall insulin concentration should be 
taken into account, because insulin concentration can rise rapidly in a short period of 
time in response to a meal, and then return to basal levels 22. Nevertheless, insulin 
transport into the brain is not rapid, but occurs over a period of hours, consistent with 
a role for insulin as a long-term regulator of energy balance 23. Leptin and insulin both 
bind to receptors located in the arcuate nucleus and thereby affect the NPY- and 
POMC-pathway leading to an inhibitory effect on appetite 5;24. 
 Ghrelin, cholecystokinin (CCK) and peptide YY (PYY) are examples of short-
term signals. Ghrelin is a circulating hormone that is synthesized in the stomach and 
that increases food intake 25. Ghrelin levels increase during fasting, rising sharply 
before and falling within one hour of a meal, suggesting that ghrelin plays a role in 
hunger and meal initiation 26. CCK is a hormone that is produced in the upper part of 
the small intestine in response to the presence of ingested food. It is released 
postprandialy and inhibits food intake 27. CCK induces satiety and decreases meal 
size by stimulating the vagal nerve projecting to the nucleus of the solitary tract 
(NTS) in the brainstem 28. PYY is a hormone that is produces in the distal part of the 
gastrointestinal tract and is released into the circulation in response to a meal 29. PYY 
can be cleaved into PYY3-36, the isoform of PYY that inhibits food intake. PYY3-36 
inhibits food intake by acting directly on the arcuate nucleus via the Y2R, a 
presynaptic inhibitory receptor on NPY neurons 30. 
 These long-term and short-term signals are regulated by interacting 
mechanisms. They cooperate, in order to integrate energy expenditure and energy 
intake, to ensure that energy homeostasis is maintained. In the obese situation, the 
mechanism fails to preserve energy homeostasis and several of these peripheral 
signals have been shown to be dysregulated as well in obesity 31-33. 
16
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Insulin resistance. 
The metabolic syndrome comprises  a cluster of anomalies that increase the risk of  
cardiovascular disease and type 2 diabetes mellitus: hyperglycemia, abdominal 
obesity, hypertriglyceridemia, hypertension and low levels of high-density lipoprotein 
(HDL) cholesterol 34-36. Insulin resistance may underlie the majority of these 
pathologies 37 and therapies that effectively reinforce insulin action may therefore 
ameliorate the risk profile of metabolic syndrome patients  38;39. Insulin resistance is 
defined as the requirement of an abnormally large amount of insulin (endogenous or 
exogenous) for a biological response 40. Insulin resistance describes a condition that 
is characterized by decreased tissue sensitivity to the action of insulin and therefore 
affects multiple organs.  
 Insulin resistance in the liver leads to the failure of insulin to suppress the 
hepatic glucose production sufficiently. Insulin affects glucose production directly via 
signaling through the hepatic insulin receptor to inhibit glycogenolysis and 
gluconeogenesis. However, it has also been suggested that insulin  suppresses 
glucose production indirectly through extrahepatic actions of insulin on muscle and 
adipose tissue to inhibit release of gluconeogenic substrates (lactate, alanine and 
glycerol) and gluconeogenic energy substrates (FFAs) 41-43. In addition, insulin 
suppresses the hepatic production of very-low-density lipoprotein (VLDL) particles. 
These inhibitory effects are also directly on the liver through the effects of insulin on 
synthesis and secretion of VLDL 44 and indirectly because insulin affects the FFA 
release from adipose tissue 45. 
 Insulin resistance in muscle and adipose tissue leads to a diminished ability of 
insulin to stimulate glucose uptake in these tissues. In muscle, insulin stimulates the 
uptake and oxidation of glucose and the formation of glycogen. Skeletal muscle can 
use both glucose and FFA as energy source and the shift between these two 
depends primarily on the availability of FFAs and exercise level. In adipose tissue, 
glucose is needed for the formation of glycerol-3-phosphate, which is necessary for 
the formation of triglycerides (TG). Insulin stimulates the glucose uptake and 
therefore promotes adipocyte TG synthesis. Insulin also inhibits the rate of TG 
lipolysis through inhibition of the lipolytic enzyme hormone sensitive lipase. 
17
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Outline of this thesis. 
The studies described in this thesis all involve the hypothesis that the hypothalamus 
is not only involved in the regulation of food intake, but also regulates insulin 
sensitivity (independent of its effects on food intake). In obesity, dysregulation of 
several hypothalamic neuropeptides and peripheral hormones that regulate food 
intake, has been observed and leads to an increased food intake. Perhaps the same 
dysregulation of these neuropeptides and hormones can cause insulin resistance as 
well.  All studies described here where performed in mice. 
 The effects of both the NPY and POMC pathway on insulin sensitivity were 
studied. In chapter 2 we describe the effects of a continuous intracerebroventricular 
(icv) infusion of NPY on insulin sensitivity. In chapter 3 the effects of icv injections of 
MTII, an agonist of the POMC pathway, is described. In chapter 4 the acute effects 
of the peripheral hormone PYY3-36 on insulin sensitivity are described. In chapter 5 
the long-term effects of PYY3-36 are investigated to examine whether PYY3-36 could 
be of use in the clinical management of obesity and insulin resistance. Finally, in 
chapter 6, the role of the peripheral hormone leptin and the role of its central 
signalling on insulin sensitivity is examined in ob/ob mice and evaluated against the 
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Abstract 
Recent evidence demonstrates that hypothalamic insulin signaling is required for 
inhibition of endogenous glucose production (EGP). The downstream mechanisms 
responsible for the effects of hypothalamic insulin receptor activation on hepatic fuel 
flux remain to be established. To establish if downregulation of Neuropeptide Y 
(NPY) release by insulin is mandatory for its capacity to suppress glucose 
production, we examined the effects of a continuous intracerebroventricular (i.c.v.) 
infusion of NPY (10 µg/h for 3-5 hours) on glucose flux during a hyperinsulinemic 
euglycemic clamp in mice. We also evaluated the effects of i.c.v. NPY administration 
on free fatty acid- and glycerol flux and very low-density lipoprotein (VLDL) 
production in this experimental context. In basal conditions, none of the metabolic 
parameters was affected by NPY infusion. In hyperinsulinemic conditions, peripheral 
glucose disposal was not different between vehicle- and NPY-infused animals. In 
contrast, hyperinsulinemia suppressed endogenous glucose production by 
approximately 8% vs. 30 % in NPY- vs. vehicle-infused mice respectively (P<0.05). 
Also, VLDL-production was significantly higher during hyperinsulinemia in NPY- 
compared with vehicle-infused mice (97.5 ± 18.0 vs. 54.7 ± 14.9 µmol/kg/h, P<0.01). 
These data suggest that the neurophysiological action of insulin to downregulate 
hypothalamic NPY release is a prerequisite for its ability to suppress hepatic fuel 




Insulin resistance is an important characteristic of obesity and type 2 diabetes 
mellitus (T2DM) 1;2. It hampers proper suppression of endogenous glucose and very 
low-density lipoprotein (VLDL) production in response to food intake. Accordingly, the 
metabolic features of obesity and T2DM include hyperglycemia and 
hypertriglyceridemia.  
It has recently been shown that hypothalamic insulin signaling is required for 
inhibition of endogenous glucose production (EGP) 3. Indeed,  intracerebroventricular 
(i.c.v.) infusion of insulin can suppress glucose production (by 40%) in the presence 
of basal circulating insulin concentrations, whereas antagonism of insulin signaling or 
24
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downregulation of insulin receptor expression in hypothalamic nuclei considerably 
impairs the ability of circulating insulin to inhibit EGP 3;4.  
The downstream mechanisms responsible for the apparent impact of 
hypothalamic insulin receptor activation on hepatic fuel flux remain to be established.  
The arcuate nucleus of the hypothalamus is a major target of insulin in the brain. This 
nucleus contains two insulin sensitive populations of neurons that exert powerful, 
opposing effects on fuel flux: pro-opiomelanocortin (POMC) neurons (stimulated by 
insulin), guiding a catabolic adaptive response to environmental cues, and NPY 
neurons (inhibited by insulin), that primarily promote anabolic adaptations 5. I.c.v. 
infusion of a melanocortin antagonist (SHU9119) does not affect the ability of 
hyperinsulinemia to inhibit endogenous glucose production, which suggests that the 
POMC pathway is not involved in the acute effects of insulin on hepatic fuel flux 3. In 
regard to the other major insulin sensitive neural route, it was reported that 
subchronic i.c.v. infusion of NPY in Spraque-Dawley rats and mice induces 
hyperinsulinemia, hyperglycemia and dyslipidemia 6;7. These findings led us to 
hypothesize that downregulation of central (hypothalamic) NPY neuronal activities by 
insulin is critical for its ability to control endogenous glucose and lipid production. To 
test this hypothesis, we examined whether infusion of NPY into the lateral cerebral 
ventricle precludes proper inhibition of endogenous fuel production during a 
hyperinsulinemic euglycemic clamp in mice. 
 
Research designs and methods 
Animals. Male C57BL/6J mice were housed in a temperature-controlled room on a 
12-hour light-dark cycle and were fed a standard mouse chow diet with free access 
to water. All animal experiments were performed in accordance with the regulations 
of Dutch law on animal welfare and the institutional ethics committee for animal 
procedures approved the protocol.  
Surgical procedures. Mice were anaesthetized with 0.5 ml/kg Hypnorm (Janssen 
pharmaceutica, Beerse, Belgium) and 12.5 mg/kg midazolam (Genthon, Nijmegen, 
the Netherlands). A 25-gauge guide cannula was stereotaxically implanted into the 
left lateral ventricle using the following coordinates from Bregma: 0.46 mm posterior, 
1.0 mm lateral end 2.2 mm ventral 8. The guide cannula was secured with two screws 
and dental cement (AgnTho’s, Lidingö, Sweden) to the skull surface. After a recovery 
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period of 1 week, adequate placement of the cannulae was tested with the feeding 
response to an i.c.v. injection of NPY (5 µg dissolved in 1 µl sterile water) (Bachem, 
Bubendorf, Germany).  
Hyperinsulinemic euglycemic clamp. Mice with free access to standard mouse 
chow and water until the beginning of the clamp experiment were used. 
Hyperinsulinemic clamps were performed under Hypnorm/Midazolam anesthesia as 
described earlier 9-13. During the entire experiment (basal and hyperinsulinemic 
period) NPY (5 µg/µl) or vehicle was administered i.c.v. at a rate of 2 µl/h (via an 
injection cannula) using an infusion pump and a 10 µl Hamilton syringe. In one series 
of experiments glucose and glycerol turnover were determined and in another series 
of experiments FFA turnover was determined. First, basal rates of glucose, glycerol 
or FFA turnover were determined by giving a primed (p) continuous (c) infusion of 
14C-glucose (p: 0.2 µCi, c: 0.3 µCi/h) (Amersham, Little Chalfont, U.K.), 3H glycerol 
(p: 0.6 µCi, c: 0.9 µCi/h) (Amersham, Little Chalfont, U.K) or 3H-oleate (p: 2 µCi, c: 3 
µCi/h) (Amersham, Little Chalfont, U.K) respectively. Subsequently, (after 80 min) 
insulin was administered in a primed (4.5 mU) continuous (6.8 mU/h) i.v. infusion for 
~1.5 h to attain steady state circulating insulin levels of ~4 ng/ml. A variable infusion 
of a 12.5% D-glucose solution was used to maintain euglycemia as determined at 10 
min intervals via tail bleeding (< 3 µl)(Freestyle, TheraSense, Disetronic Medical 
Systems BV, Vianen, The Netherlands). Blood samples (60 µl) were taken during the 
basal period (after 60 and 80 min) and during the clamp period (20 min prior to- and 
by the end of the clamp) to determine the plasma concentration of glucose, glycerol, 
FFA and insulin and plasma 14C-glucose, 3H-glycerol and 3H-oleate specific activities. 
At the end of the clamp, mice were either sacrificed and their livers isolated and 
frozen in liquid nitrogen for subsequent analysis, or mice were used to determine 
VLDL-production. 
VLDL-production. Mice were given a continuous i.c.v. infusion of NPY (5 µg/µl) or 
vehicle at a rate of 2 µl/h. Mice were intravenously injected with 500 mg of Triton 
WR-1339 (Sigma, St. Louis, MO, USA) per kg body weight as a 10% (w/w) solution 
in sterile saline. Serum VLDL clearance is virtually completely inhibited under these 
circumstances 14. Blood samples (20 µl) were taken on t=0, 30, 60 and 90 min after 
Triton injection and used for determination of plasma triglycerides (TG) 
concentration. Plasma TG concentrations were related to body weight and hepatic 
VLDL-TG production was calculated from the slope of the curve and expressed as 
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µmol/kg/min. Triton injections were given either under basal conditions (90 min after 
the beginning of the i.c.v. infusion) or under hyperinsulinemic conditions (after the 
clamp experiment). At the end of the experiment, mice were sacrificed and liver 
samples were taken and frozen in liquid nitrogen for subsequent analysis. 
Analytical procedures. Plasma levels of glucose, glycerol, FFA, TG and 
corticosterone were determined using commercially available kits (Sigma, St. Louis, 
MO, USA; Boehringer Mannheim, Mannheim, Germany and Wako, Neuss, Germany; 
Alpco, Windham, NH, USA). Plasma insulin, glucagon and NPY concentration were 
measured by radioimmunoassay (Linco Research Inc., St. Charles, MO, USA; Alpco, 
Windham, NH, USA; Peninsula Laboratories, San Carlos, CA, USA). Total plasma 
14C-glucose and 3H-glycerol was determined in 10 µl plasma and in supernatants 
after trichloroacetic acid (20%) precipitation and water evaporation to eliminate 
tritiated water. Total plasma 3H-oleate was determined in 7.5 µl plasma after 
extraction of lipids by a modification of Bligh and Dyer’s method 15. In short, 7.5 µl 
plasma was dried and resolved in 100 µl water. Then 1.1 ml demi-water and 4.5 ml 
methanol:chloroform (2:1) was added and mixed thoroughly, after which 1.5 ml 
chloroform was added and mixed and finally, 1.5 ml demi-water was added and 
mixed. After centrifugation, the chloroform layer was collected and FFA fraction was 
separated from the other lipid components by thin-layer chromatography (TLC) on 
silica gel plates. Content of TG in liver was determined as described before 16. 
Briefly, 10-20 µg of tissue was homogenized in phosphate-buffered saline (PBS) and 
samples were taken for measurement of protein content 17. Lipids were extracted and 
TG fraction was separated from the other lipid components by high performance thin-
layer chromatography (HPTLC) on silica gel plates. 
Calculations. Turnover rates of glucose, FFA and glycerol (µmol/min/kg) were 
calculated during the basal period and during the steady-state portion of the clamp as 
the rate of tracer infusion (dpm/min) divided by the plasma specific activity of 14C-
glucose, 3H-oleate or 3H-glycerol (dpm/µmol). The ratio was corrected for body 
weight. EGP was calculated as the difference between the tracer-derived rate of 
glucose appearance and the infusion rate of glucose. 
Statistical analysis. Differences between groups were determined by Mann-Whitney 
non-parametric test for 2 independent samples. A P-value < 0.05 was considered 
statistically significant. All values shown represent mean ± SD. 
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Results 
Plasma parameters. Body weight, plasma glucose, FFA, glycerol, insulin, glucagon 
and corticosterone in basal and hyperinsulinemic conditions are shown in table 1. In 
basal conditions, no differences in plasma parameters were detected between 
vehicle- and NPY-infused animals. In steady-state clamp conditions, insulin, 
glucagon and corticosterone levels and plasma glucose concentrations were similar 
in both groups. Hyperinsulinemia suppressed both FFA and glycerol levels to a 
similar extent in vehicle- and NPY-infused mice. Plasma NPY levels at the end of the 
clamp period were similar in both groups (4.0 ± 2.0 ng/ml in vehicle-infused mice vs. 
5.1 ± 2.4 ng/ml in NPY-infused animals). 
 
Table 1. Plasma parameters in mice that received an i.c.v.-infusion of NPY or vehicle under basal or 
hyperinsulinemic conditions. Values represent mean ± SD for at least 5 mice per group. 1 These data 
are  based on 2 mice only and therefore have to be considered with caution.  
 
  Basal   Hyperinsulinemic  
 Vehicle NPY Vehicle NPY 
Body weight (g) 23.3 ± 1.2 22.2 ± 1.2 23.3 ± 1.2 22.3 ± 1.4 
Glucose (mmol/l) 7.0 ± 1.4 6.8 ± 1.8 7.5 ± 1.2 7.7 ± 1.2 
FFA (mmol/l) 0.7 ± 0.2 0.7 ± 0.3 0.2 ± 0.1 0.3 ± 0.1 
Glycerol (mmol/l) 0.7 ± 0.2 0.7 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
Insulin (ng/ml) 0.8 ± 0.3 1.0 ± 0.6 3.5 ± 0.9 3.9 ± 1.1 
Glucagon (pmol/l) 100.0 ± 12.4 99.1 ± 22.0 71.3 ± 14.5 66.8 ± 22.2 
Corticosterone (ng/ml) 29.6 ± 5.4 21.0 ± 9.9 26.2 ± 7.2 25.6 ± 17.61 
  
 
Glucose turnover. The rate of glucose infusion necessary to maintain euglycemia 
during insulin infusion was significantly lower in NPY-infused mice than in vehicle-
infused animals (28.6 ± 8.6 vs. 59.8 ± 12.8 µmol/min/kg, P<0.01; Figure 1), indicating 
that i.c.v. NPY administration acutely induces insulin resistance. In basal conditions, 
glucose disposal was similar in NPY- and vehicle-infused mice (146.2 ± 40.9 vs. 
138.1 ± 30.0 µmol/min/kg, respectively; Figure 2).  
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Hyperinsulinemia barely increased glucose disposal and the subtle increase it 
brought about was of similar magnitude in NPY- and vehicle-infused animals (163.2 ± 
22.8 vs. 151.1 ± 24.8 µmol/min/kg, respectively). In contrast, endogenous glucose 
production (EGP), which was similar in basal conditions, was adequately suppressed 
by insulin in vehicle-infused animals (by ~30%, P<0.01), whereas it was much less 
affected in NPY-infused mice (~8%, P=NS; P<0.05 for difference between NPY- and 









    


















Figure 2. Glucose disposal (a) and endogenous glucose production (b) in mice that received an i.c.v.-
infusion of NPY or vehicle before (basal) and after (hyperinsulinemic) the initiation of a 
hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 5 mice per group. 







Figure 1. Glucose infusion rate (GIR) in mice 
that received an i.c.v.-infusion of NPY or 
vehicle during a hyperinsulinemic euglycemic 
clamp. Values represent mean ± SD for at 
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FFA and glycerol turnover. Basal rates of FFA (16.6 ± 6.5 vs. 18.1 ± 7.8 
µmol/min/kg) and glycerol turnover (7.3 ± 3.5 vs. 6.8 ± 1.4 µmol/min/kg) were not 
different between vehicle and NPY infused animals (Figure 3). Hyperinsulinemia 
suppressed both FFA and glycerol turnover to a similar extent in both groups (6.6 ± 
2.3 vs. 9.0 ± 4.8 µmol/min/kg and 4.6 ± 1.6 vs. 4.3 ± 1.0 µmol/min/kg in vehicle and 
NPY-infused animals for FFA and glycerol turnover, respectively). 
VLDL-production. VLDL-production was similar in both groups in basal conditions 
(82.5 ± 20.4 (vehicle) vs. 68.8 ± 34.9 (NPY) µmol/kg/h; Figure 4), whereas it 
remained significantly higher in hyperinsulinemic conditions during NPY infusion 






















Figure 3. Free fatty acids (FFA) turnover (a) and glycerol turnover (b) in mice that received an i.c.v.-
infusion of NPY or vehicle before (basal) and after (hyperinsulinemic) the initiation of a 
hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 5 mice per group. 













































































Figure 4. VLDL production rate in mice that received an i.c.v.-infusion of NPY or vehicle under basal 
(a) or hyperinsulinemic (b) conditions. Values represent mean ± SD for at least 5 mice per group. 
*P<0.01 vs. vehicle. 
 
Discussion 
This study demonstrates that i.c.v. infusion of NPY acutely impairs the ability of 
insulin to inhibit glucose and VLDL production. In contrast, NPY administration did 
not affect insulin's stimulatory action on glucose disposal and inhibitory effect on 
lipolysis. We infer that suppression of central NPY neuronal activities by insulin may 
be pivotal for its ability to suppress endogenous glucose and VLDL production.  
  One of the major targets of insulin in the brain is an intricate neuronal circuit in 
the arcuate nucleus that plays a critical role in the regulation of energy balance and 
fuel flux. This circuit comprises a catabolic regulatory pathway, primarily consisting of 
neurons co-expressing POMC and Cocaine and Amphetamine Related Transcript 
(CART). These POMC/CART neurons effectively counterbalance the actions of an 
anabolic pathway, comprising NPY/Agouti related protein (AgRP) neurons 5. Insulin 
has reciprocal regulatory effects on these neurons: it stimulates the activity of POMC 
neurons, while it inhibits neuronal NPY release. POMC conveys its catabolic 
message via α-melanocyte stimulating hormone (α-MSH), a derivative peptide, which 
activates melanocortin 3 and 4 receptors (MCR3/4). Acute i.c.v. infusion of a potent 
MCR3/4 antagonist did not affect the ability of circulating insulin to inhibit glucose 
production 3, which indicates that the inhibitory action of insulin on glucose production 
does not require the stimulatory impact of hypothalamic insulin receptors on 
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does impair insulin action in rats, probably via effects on food intake and body fat 
content 18). To explain the acute effects of hypothalamic insulin signaling on 
endogenous glucose production 3, we explored the impact of i.c.v. NPY infusion on 
the metabolic effects of hyperinsulinemia during a euglycemic clamp. Our data 
clearly show that NPY impairs the ability of hyperinsulinemia to suppress 
endogenous (primarily hepatic) glucose production in this experimental context. 
Furthermore, insulin does not only suppress hepatic glucose production, but also 
inhibits VLDL production 19;20 and our results indicate, that i.c.v. NPY administration 
hampers this metabolic action of insulin as well. We infer that the primary 
neurophysiological effect of insulin to inhibit neuronal NPY release may be critical for 
its capacity to inhibit (hepatic) glucose and VLDL production. 
  In contrast to its apparent impact on glucose and VLDL production, NPY 
administration did not alter the effects of hyperinsulinemia on glucose disposal or 
lipolysis. The latter observation supports the notion that the effect of NPY on the 
ability of insulin to modulate VLDL metabolism was a direct hepatic effect and not 
mediated via enhanced flux of free fatty acids to the liver, brought about by any 
potential impact of NPY on lipolysis. The former finding agrees with data reported by 
Obici 3, which indicate that hypothalamic insulin signaling does not (acutely) affect 
insulin mediated glucose disposal (despite its clear inhibitory effect on hepatic insulin 
action). Collectively, the current knowledge suggests that downregulation of 
hypothalamic NPY by insulin may be a prerequisite for its acute inhibitory impact on 
endogenous glucose and VLDL production, whereas it does not directly affect fuel 
flux in other peripheral tissues. 
  NPY receptors are not only present in the brain, but in many peripheral tissues 
as well 21-23. To dismiss the possibility that i.c.v. NPY infusion modulated insulin 
sensitivity via activation of peripheral receptors (after leakage through the blood brain 
barrier into the circulation), we measured plasma NPY levels at the end of the i.c.v.-
infusion period. NPY concentrations were similar in vehicle and NPY-infused 
animals, demonstrating that the effects of NPY on glucose and VLDL-production that 
we observed were not due to activation of peripheral NPY receptors. 
 It is apt to consider that anesthesia may impact on the neuromodulatory 
effects of peptides. However, our findings agree with and corroborate a similar study 
performed in conscious unrestrained rats without access to food 24. The similarity of 
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the results of either study supports the position that anesthesia did not affect our data 
to a major extent and adds further credibility to our main message. 
  It is important to recognize, that we probably infused a pharmacological dose 
of NPY, which precludes a definite inference as to whether NPY is a second 
messenger downstream the brain insulin receptor involved in the physiological 
control of fuel metabolism. Also, the present study does not rule out the possibility 
that i.c.v. NPY administration hampers the capacity of insulin to suppress glucose 
and VLDL production via other mechanistic routes than those downstream its arcuate 
receptor. Indeed, NPY has a variety of neuroendocrine effects that may also be 
involved. For example, it stimulates the activity of the pituitary adrenal ensemble 25 
and adrenalectomy was shown to prevent or reduce some metabolic effects of 
subchronic i.c.v. NPY administration, like hyperphagia, weight gain and 
hyperinsulinemia 25-28. Corticosteroids enhance endogenous glucose production 
primarily via stimulation of gluconeogenesis without affecting glycogenolysis 29. 
However, circulating levels of corticosterone were not affected by NPY administration 
in the present study, which obviously argues against the position that the pituitary 
adrenal ensemble is involved in the acute effects of NPY on hepatic insulin 
sensitivity. We also checked if NPY enhances plasma glucagon concentrations to 
stimulate EGP, but glucagon levels did not differ between NPY and vehicle treated 
animals. Thus, it remains a challenge to unveil the messengers that relay NPY 
signals from the brain to the liver to control glucose and VLDL production. 
  Our data imply that insulin resistant neural circuits and related NPY neuronal 
activities may be involved in the pathogenesis of some of the features of the 
metabolic syndrome. High fat diet-induced obesity syndromes in rodents (and many 
genetically engineered obesity models as well) are marked by hyperglycemia and 
hypertriglyceridemia. Human obesity is also frequently complicated by these adverse 
metabolic sequelae, which are partly brought about by impaired ability of insulin to 
suppress endogenous glucose and VLDL production. High fat feeding was shown to 
induce both insulin resistance and (as a corollary) high NPY expression levels in the 
arcuate nucleus of the rodent brain 30;31. Other obese animal models are also 
characterized by high NPY neuronal activity 32-35. Given the effects of hypothalamic 
insulin on hepatic fuel flux, it is conceivable that brain insulin resistance and 
unleashed NPY neuronal activity are involved in the pathogenesis of hyperglycemia 
and hypertriglyceridemia as sequelae of high fat feeding and obesity. In this scenario, 
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NPY receptor antagonistic drugs may be appropriate tools to treat these metabolic 
anomalies, which predispose to type 2 diabetes mellitus and cardiovascular disease. 
  In summary, we here provide evidence that i.c.v. NPY administration 
precludes the inhibition of hepatic glucose and VLDL production by circulating insulin. 
This finding may imply that the increased hypothalamic NPY levels that are typically 
observed in various obese animal models underlie hepatic insulin resistance and 
associated metabolic anomalies in these models. NPY receptor antagonists may 
therefore be useful therapeutical tools in the clinical management of insulin 
resistance and type 2 diabetes.  
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Abstract 
Aims/hypothesis. The present study was conducted to evaluate the effects of 
central administration of melanotan II (MTII), a MC3/4 receptor agonist, on hepatic 
and whole body insulin sensitivity, independent of food intake and body weight. 
Methods. 225 ng of MTII was injected in 3 aliquots over 24 hours into the left lateral 
ventricle in male C57Bl/6 mice without access to food. The control group received 3 
distilled water injections. Whole-body and hepatic insulin sensitivity were measured 
by hyperinsulinaemic-euglycaemic clamp in combination with 3H-glucose infusion. 
GLUT-4 mRNA expression was measured in skeletal muscle. 
Results. Plasma glucose and insulin concentrations during basal and 
hyperinsulinaemic conditions were similar in MTII- and placebo-treated mice. 
Endogenous glucose production (EGP) and glucose disposal in the basal state were 
significantly higher in MTII-treated mice compared to the control group (71±22 vs. 
43±12 µmol/min/kg, p<0.01). During hyperinsulinaemia, glucose disposal was 
significantly higher in MTII-treated mice (151±20 vs. 108±20 µmol/min/kg, p<0.01). In 
contrast, the inhibitory effect of insulin on EGP was not affected by MTII (relative 
decrease of EGP: 45±27 vs. 50±20%). GLUT-4 mRNA expression in skeletal muscle 
was significantly increased in MTII-treated mice (307±94 vs. 100±56%, p<0.01). 
Conclusions/interpretation. Intracerebroventricular administration of MTII acutely 
increases insulin-mediated glucose disposal, whereas it does not affect insulin’s 
capacity to suppress EGP in C57Bl/6 mice. These data indicate that central 
stimulation of MC3/4 receptors modulates insulin sensitivity in a tissue specific 
manner, independent of its well-known impact on feeding and body weight.  
 
Introduction 
The hypothalamus integrates a multitude of behavioural and metabolic adaptations to 
food intake and starvation, necessary to maintain fuel homeostasis despite profound 
environmental variations in nutrient availability 1. Two types of neurons in the arcuate 
nucleus of the hypothalamus are of major importance for the control of these 
processes: neurons co-expressing Agouti related protein (AgRP) and neuropeptide Y 
(NPY), and neurons expressing pro-opiomelanocortin (POMC), the molecular 
precursor of alpha-melanocyte stimulating hormone (α-MSH) 2. α-MSH binds to and 
stimulates melanocortin (MC) receptors. AgRP can bind to MC receptors as well, and 
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thereby inhibit the POMC pathway 3. NPY and POMC neuropeptides exert opposing 
effects on food intake and fuel homeostasis. NPY acts to promote anabolic 
pathways, whereas α-MSH counteracts the effects of NPY 4-6. For instance, during 
food deprivation NPY/AgRP neuronal activity is high, whereas POMC/α-MSH 
expression levels are low 5, and this setting of the arcuate neuronal circuitry strongly 
stimulates food intake and reduces energy expenditure 7.  
Apart from its impact on food intake, intracerebroventricular (icv) 
administration of NPY acutely hampers insulin's capacity to inhibit hepatic glucose 
and VLDL production in C57Bl/6 mice, whereas insulin sensitivity of muscle and 
adipose tissue remains unaffected 8. Conversely, chronic (7 days) icv infusion of α-
MSH enhances peripheral and hepatic insulin sensitivity in rats through stimulation of 
the MC3/4 receptor 9 and POMC gene overexpression ameliorates insulin resistance 
in leptin-deficient mice via a mechanism that is independent of its effects on food 
intake and body weight 10.  In the latter studies, the effects on insulin sensitivity occur 
in the presence of a concomitant reduction in food intake and fat mass, which 
precludes distinction of putative direct effects of α-MSH or MC4 receptor on insulin 
sensitivity from indirect effects via feeding and body composition.  
In addition to the effect of MC4 receptor activation on insulin sensitivity, Fan et 
al documented decreased insulin concentration after central activation of the 
melanocortin neuronal circuitry and increased levels of insulin in MC4 receptor 
knockout mice, even before the onset of detectable hyperphagia or obesity 11. In 
humans, MC4 receptor mutations are associated with obesity 12;13.  
The aim of the present study was to document the direct effects of activation 
of MC3/4 receptors on insulin sensitivity (i.e. via other mechanistic routes than 
feeding and fat mass). Therefore, we injected melanotan II (MTII) 14, an agonist of the 
MC3/4 receptor 15 icv, and quantified hepatic and peripheral insulin sensitivity of 
glucose metabolism during a hyperinsulinaemic euglycaemic clamp in mice without 
access to food. 
 
Research designs and methods 
Animals. Male, 3 months old C57Bl/6 mice (originated from the Jackson 
Laboratories and bred in our own animal facility) were housed in a temperature and 
humidity controlled room on a 12-hour-light-dark cycle with free access to standard 
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mouse chow and water. All animal experiments were performed in accordance with 
the principles of laboratory animal care and regulations of Dutch law on animal 
welfare and the institutional ethics committee for animal procedures approved the 
protocol.  
Surgical procedures. Mice were anaesthetised with 0.5 mg/kg Medetomidine 
(Pfizer, Capelle a/d IJssel, the Netherlands), 5 mg/kg Midazolam (Roche, Mijdrecht, 
the Netherlands), and 0.05 mg/kg Fentanyl (Janssen-Cilag, Tilburg, the Netherlands). 
A 25-gauge guide cannula was stereotactically implanted into the left lateral ventricle 
using the following coordinates from Bregma: 0.46 mm posterior, 1.0 mm lateral end 
2.2 mm ventral 16;16. The guide cannula was secured with two screws and dental 
cement (AgnTho’s, Lidingö, Sweden) to the skull surface. After a recovery period of 1 
week, adequate placement of the cannulae was tested by measuring the feeding 
response to an acute icv injection of NPY (5 µg dissolved in 1 µl sterile water) 
(Bachem, Bubendorf, Germany).  
Hyperinsulinaemic euglycaemic clamp. Mice fasted for 24 hours (with food 
withdrawn at 09.00 am the day before the experiment) were used. At 9.00 hours and 
17.00 hours the day before the experiment and at 8.45 hours on the day of the 
experiment mice were given 75 ng (in 1.5 µl distilled water) MTII (PhoenixEurope 
GmbH, Karlsruhe, Germany) or 1.5 µl distilled water (control group) icv. This dose of 
MTII was based on data from Murphy et al 17), who showed inhibition of food intake 
using this dose. During icv injections, mice were lightly anaesthetised with isoflurane. 
All experiments were performed at 09.00 hours. Hyperinsulinaemic euglycaemic 
clamps were performed as described earlier 18;19. During the experiments, mice were 
sedated with 6.25 mg/kg Acepromazine (Sanofi sante animale, Libourne Cedex, 
France) 6.25 mg/kg Midazolam (Roche, Mijdrecht, the Netherlands), and 0.3125 
mg/kg Fentanly (Janssen-Cilag, Tilburg, the Netherlands). 
Basal rates of glucose turnover were measured by giving a primed (0.7 µCi) 
continuous (1.2 µCi/h) infusion of 3H-glucose (Amersham, Little Chalfont, UK) for 80 
min. Subsequently, insulin was administered in a primed (4.1 mU) continuous (6.8 
mU/h) i.v. infusion for 2 to 3 hours to attain steady state circulating insulin levels of 
about 4 ng/ml. The 3H-glucose infusion (1.2µCi/h) was continued. A variable infusion 
of 12.5% D-glucose (in PBS) solution was also started and adjusted to maintain 
blood euglycaemia (measured at 10 minute intervals via tail bleeding, Freestyle, 
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TheraSense, Disetronic Medical Systems BV, Vianen, the Netherlands). 
Bloodsamples (60 µl) were taken during the basal period (after 60 and 80 minutes) 
and during the clamp period (when glucose levels in the blood were stable and 20 
and 40 minutes later) for determination of plasma glucose, NEFA, insulin and 3H-
glucose specific activity.  
mRNA expression of GLUT-4. A real time polymerase chain reaction (RT-PCR) was 
used to measure mRNA expression levels of GLUT-4 in skeletal muscle. Skeletal 
muscle was taken out in additional groups of mice directly at 10.30 hours. after a 24h 
fast and 3 icv injections with either MTII or vehicle (injections at the same time-points 
as in the hyperinsulinaemic euglycaemic clamp experiment). Muscle was 
homogenised in 1.2 ml RNA-Bee (Tel-Test, Inc, Texas, US) and total RNA was 
extracted according to Chomzcinsky and Sacchi 20. The amount of RNA was 
determined by spectrophotometry (ND-1000 spectrophotometer, Nanodrop®) at a 
wavelength of 260 nm. The quality was checked by the ratio of absorption at 260 nm 
and absorption at 280 nm. Complementary DNA (cDNA) was obtained of total RNA. 
For RT-PCR, forward and reverse primers and TaqMan probe were designed from 
mice specific sequence data (Entrez, National Institutes of Health; and Ensembl, 
Sanger Institute) using computer software (Primer Express, Applied Biosystems). For 
each of the genes a Blast Search was done to reveal that sequence homology was 
obtained only for the target gene. Forward, reverse primers and TaqMan probe (5’ 
CCATGAGATCTGAGGCCACA 3’; 5’ GTATTTGCCGAAGTTGTAGCCG 3’; 5’ 
CAAGGGCAAGATCATCATGCACGACC 3’) of GLUT-4 were used. The TaqMan 
probe was 5’-6-carboxyfluorescein (FAM) and 3’- (BHQ1) labelled. GAPDH (5’ VIC 
and 3’ BHQ1, Applied Biosystems) and Cyclophilin (5’ TET and 3’ BHQ1, 5’ 
CAAATGCTGGACCAAACACAA 3’; 5’ GCCATCCAGCCATTCAGTCT 3’; 5’ 
CCGGTTCCCAGTTTTTTATCTGCACTGCC 3’) were used as housekeeping genes. 
PCR amplification was performed in a total reaction volume of 12.5 µl. The reaction 
mixture consisted of qPCR™ MasterMix (Eurogentec, Belgium), the optimal primer 
and probe concentrations of GLUT-4 and the endogenous control, nuclease free 
water and cDNA. An identical cycle profile was used for all genes: 50°C for 2 min + 
95°C for 10 min + [95°C for 15 sec + 60°C for 1 min] * 40 cycles. Data were analysed 
using a comparative critical threshold (Ct) method where the amount of target 
normalised to the amount of endogenous control (GAPDH/cyclophilin) and relative to 
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the control sample is given by 2-∆∆Ct (Applied Biosystems). All samples were run 
together allowing relative comparisons of the samples. 
Analytical procedures. Plasma glucose and NEFA levels were determined using a 
commercially available kit (Instruchemie, Delfzijl, The Netherlands; Wako Pure 
Chemical Industries, Osaka, Japan). Plasma insulin and corticosterone 
concentrations were measured by Elisa (both ALPCO Diagnostics, Windham, NH, 
USA). For the determination of plasma 3H glucose, plasma was deproteinised with 
20% trichloroacetic acid, dried to remove water, resuspended in distilled water and 
counted with scintillation fluid (Ultima Gold, Packard, Meridien, Connecticut, USA). 
Calculations. Turnover rate of glucose (µmol/min/kg) was calculated during the 
basal period and in steady-state clamp conditions as the rate of tracer infusion 
(dpm/min) divided by the plasma specific activity of 3H-glucose (dpm/µmol). The ratio 
was corrected for body weight. EGP was calculated as the difference between the 
tracer-derived rate of glucose appearance and the glucose infusion rate.   
Statistical analysis. Data are presented as mean ± standard deviation. Differences 
between groups were determined by Mann-Whitney U test for 2 independent 
samples. A P-value <0.05 was considered statistically significant. 
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Results 
Plasma parameters. Body weight, plasma corticosterone, glucose, NEFA and 
insulin concentrations in basal and hyperinsulinaemic conditions are shown in Table 
1. In the basal state, these parameters did not differ between MTII- and vehicle 
treated animals. In steady state hyperinsulinaemic conditions, plasma NEFA levels 
decreased ~2-fold while insulin concentrations increased ~10 fold as expected. No 
differences were observed in plasma glucose, insulin and NEFA levels between 
MTII- and vehicle-treated mice during hyperinsulinaemia.  
 
Table 1. Body weight, plasma corticosterone, NEFA, glucose and insulin concentration in vehicle 
(n=10) and MTII (n=8) mice. Values are expressed as means ± SD. n.d. is not determined. 
 
 
Glucose turnover. In basal conditions, EGP (and thereby glucose disposal) was 
significantly higher in MTII treated animals compared to vehicle treated mice (71 ± 22 
vs. 43 ± 10 µmol/min/kg, respectively, p<0.01). During the hyperinsulinaemic period, 
the rate of glucose infusion necessary to maintain euglycaemia was significantly 
higher in MTII- than in vehicle-treated animals (114 ± 23 vs. 85 ± 20 µmol/min/kg, 
p<0.05). Accordingly, the glucose disposal rate was significantly higher in MTII 
treated animals (151 ± 20 vs. 108 ± 20 µmol/min/kg, resp., p<0.01, Figure 1a). In 
contrast, hyperinsulinaemia suppressed EGP to a similar extent in MTII- vs. vehicle-
treated animals (45 ± 27% vs. 50 ± 20%, ns, Figure 1b).  
  Basal   Hyperinsulinemic  
 Vehicle MTII Vehicle MTII 
Body weight (g) 17.9 ± 1.7 18.9 ± 1.6  -   -  
Corticosterone (mmol/l) 33.3 ± 17.5 37.8 ± 12.4 n.d. n.d. 
Glucose (mmol/l) 5.8 ± 1.0 6.7 ± 1.2 8.4 ± 1.0 8.2 ± 2.4 
NEFA (mmol/l) 0.55 ± 0.17 0.62 ± 0.17 0.26 ± 0.14 0.24 ± 0.08 
Insulin (ng/ml) 0.31 ± 0.11 0.31 ± 0.07 3.8 ± 2.9 3.7 ± 2.7 
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mRNA expression of GLUT-4. GLUT-4 mRNA expression in skeletal muscle was 
higher in the MTII treated group compared to vehicle-treated mice (307 ± 94 vs. 100 










































































Figure 1. Insulin mediated glucose disposal (a) and inhibition of endogenous glucose production (b) 
by insulin in 24 hours fasted mice that received icv injections of MTII (n=10) or vehicle (n=8). Values 



























This study shows, that activation of MC3/4 receptors enhances whole body sensitivity 
of glucose metabolism for insulin action in mice via other mechanistic routes than 
feeding and fat mass. In particular, MTII promotes insulin mediated glucose disposal, 
whereas it leaves the capacity of insulin to suppress EGP unaffected. These 
observations are in line with the emerging notion, that neural circuits control insulin 




Figure 2. GLUT4 mRNA 
expression levels in 24 hours 
fasted mice that received 
injections of MTII (n=6) or 
vehicle (n=7) in basal conditions. 
*P<0.01 vs. vehicle. 
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Interestingly, GLUT-4 mRNA was increased in muscle of MTII treated animals, 
which suggests, that activation of MC3/4 receptors enhances GLUT-4 gene-
expression to promote glucose uptake. The downstream mechanisms that actuate 
the effects of hypothalamic neuronal circuits on muscle GLUT-4 mRNA expression 
remain to be fully elucidated. It cannot be ruled out that MTII increased locomotor 
activity and subsequently GLUT-4 mRNA expression in muscle. However, this seems 
unlikely since other studies did not observe any increase in locomotor activity after 
central administration of MTII 14;17. Additional studies are required to elucidate the 
mechanisms involved in the modulation of insulin sensitivity by central administration 
of MTII. 
Glucose production in the basal state was higher in mice treated with MTII, 
whereas MTII did not affect the capacity of insulin to suppress EGP. Thus, central 
melanocortin pathways appear to directly impact endogenous glucose output. 
Although Fan et al. [11] documented decreased plasma insulin concentrations after 
icv administration of MTII, we did not find significant changes in basal plasma insulin 
concentrations as a potential explanation for the observed increase in basal glucose 
production. As Fan et al injected more than ten times the amount we injected, this 
discrepancy may be explained by the difference in doses used.  Since MTII has been 
shown to activate the sympathetic nervous system 21;22 and sympathetic outflow can 
promote glucose production 23, it is conceivable that the autonomic nervous system 
relays signals from the hypothalamus to peripheral tissues to modulate glucose 
metabolism. Unfortunately, our study does not provide data to evaluate this 
possibility. Alternatively, the brain interacts with the liver via the hypothalamo-
pituitary-adrenal axis (HPA). Corticosteroids stimulate glucose production 24 and HPA 
activity is under strict control of the hypothalamus. In fact, corticotrophin releasing 
hormone (CRH) neurons in the paraventricular nucleus of the hypothalamus express 
MC4 receptors and central MTII injection acutely enhances CRH and corticosterone 
release in rats 25. However, MTII did not modify circulating corticosterone 
concentrations in our experimental setting, which refutes the thesis that central 
melanocortin pathways modulated the HPA axis to enhance glucose output in this 
study. Interestingly, short-term fasting is accompanied by a decrease in EGP 26;27, 
and POMC/α-MSH mRNA expressions decrease concomitantly 5. It is therefore 
tempting to speculate, that blunted melanocortin signalling is involved in the 
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decrease in EGP during fasting. In this scenario, administration of MTII may have 
prevented the normal decline in EGP associated with fasting in the present study.  
Although MTII increased basal EGP, it did not appear to affect insulin’s 
capacity to suppress it. A previous paper 9 reports that chronic (7 days) icv infusion of 
α-MSH reinforces insulin action on glucose production (as well as on glucose 
disposal) in rats. However, this effect occurred in the presence of concomitant 
diminutions of food intake and body adiposity and both of these long-term sequelae 
of MTII administration can impact insulin sensitivity. Our data indicate that activation 
of melanocortin circuits, through a mechanism that is independent of food intake and 
body weight, enhances insulin sensitivity and that insulin action on glucose disposal 
is more sensitive to manipulation of MC3/4 receptors than its capacity to suppress 
EGP.  
We recently showed that icv infusion of NPY in C57Bl/6 mice acutely hampers 
insulin's inhibitory effect on EGP, whereas it does not appear to affect insulin 
mediated glucose disposal 8. We now show, that activation of melanocortin circuits 
reinforces insulin action on glucose disposal, while suppression of glucose 
production remains unaffected. NPY and melanocortin circuits in the arcuate nucleus 
play critical roles in the control of fuel homeostasis in the face of fluctuations in 
nutrient availability. NPY neurons, active during fasting, stimulate feeding and inhibit 
energy expenditure, whereas melanocortin circuits, suppressed in fasting conditions, 
counteract NPY to exert opposing effects on energy balance. These behavioural and 
metabolic actions serve to protect the body against the perils of famine. Our data 
suggest that the brain also modulates glucose metabolism to further reinforce the line 
of defence: enhanced activity of NPY neurons promotes glucose production, whereas 
reduced melanocortin activity hampers glucose disposal in fasting conditions, 
keeping glucose available as pivotal fuel for the brain. Conversely, diminished 
NPY'ergic and increased melanocortin signalling allow insulin to appropriately 
suppress glucose output and promote glucose disposal in response to food intake. 
The current findings may imply that MC-3/4 receptor agonists can serve as "insulin 
sensitisers" in the treatment of the metabolic syndrome and type 2 diabetes mellitus. 
However, tachyphylaxis to chronic MTII administration has been observed in mice 
and rats 28;29. In addition, the present study shows that MTII increases basal EGP. 
Thus, the impact of chronic MTII administration on glucose metabolism in (insulin 
resistant) animal models and humans remains to be established. 
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In conclusion, the present study shows that activation of central melanocortin-
3/4 receptors by melanotan II enhances insulin sensitivity of whole body glucose 
disposal, independent of food intake and fat mass, whereas it does not affect insulin's 
ability to suppress EGP. These observations are in line with the emerging notion, that 
neural circuits, apart from their effects on feeding, modulate insulin sensitivity to 
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Abstract 
PYY3-36 is released by the gut in response to nutrient ingestion. It modulates the 
activities of orexigenic neuropeptide Y (NPY) neurons and anorexigenic pro-
opiomelanocortin (POMC) neurons in the hypothalamus to inhibit food intake. As 
both NPY and POMC have been shown to also impact insulin action, we wondered 
whether PYY3-36 could improve insulin sensitivity. To address this question, we 
examined the acute effect of intravenous PYY3-36 on glucose and free fatty acid 
(FFA) flux during a hyperinsulinemic euglycemic clamp in mice maintained on a high 
fat diet for 2 weeks prior to the experiment. We also evaluated the effects of PYY3-36 
infusion on glucose uptake in muscle and adipose tissue in this experimental context. 
In basal conditions, none of the metabolic parameters was affected by PYY3-36. In 
hyperinsulinemic conditions, glucose disposal was significantly increased in PYY3-36-
infused- compared with vehicle-infused mice (103.8 ± 10.9 vs. 76.1 ± 11.4 
µmol/min/kg, respectively, P=0.001). Accordingly, glucose uptake in muscle and 
adipose tissue was greater in PYY3-36-treated animals, although the difference with 
controls did not reach statistical significance in adipose tissue (muscle: 2.1 ± 0.5 vs. 
1.5 ± 0.5 µmol/ g tissue, P=0.049; adipose tissue: 0.8 ± 0.4 vs. 0.4 ± 0.3 µmol/ g 
tissue; P=0.08). In contrast, PYY3-36 did not impact insulin action on endogenous 
glucose production or FFA metabolism. These data indicate that PYY3-36 reinforces 
insulin action on glucose disposal in mice fed a high fat diet, through a mechanism 
that is independent of food intake and body weight. In contrast, it leaves glucose 
production and lipid flux largely unaffected in this experimental context. 
 
Introduction 
Peptide YY (PYY) belongs to a family of peptides that is critically involved in the 
regulation of appetite. It is synthesized in specialized cells (L-cells) that are found 
primarily in the distal gastro-intestinal tract. Circulating PYY levels rise within 15 
minutes after a meal in proportion to the amount of calories ingested and remain 
elevated for about 6 hours 1. The two natural forms of this peptide, PYY1-36 and PYY3-
36, have opposing effects on food intake 2: PYY1-36 stimulates appetite whereas PYY3-
36 (the major circulating form) inhibits feeding 3-5.   
 PYY3-36 reduces food intake by acting on appetite regulation centers in the 
hypothalamus 3;6. Specifically, PYY3-36 is an agonist of the presynaptic NPY Y2 
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receptor (Y2R), which inhibits NPY neuronal activity in the arcuate nucleus and 
thereby activates adjacent pro-opiomelanocortin (POMC) neurons 3. In addition to 
their critical role in the control of feeding, both NPY and POMC affect insulin action. 
Intracerebroventricular infusion of NPY induces hyperinsulinemia and insulin 
resistance in rats 7;8. In contrast, central administration of α-melanocyte stimulating 
hormone (α-MSH), a splice-product of the POMC peptide, enhances insulin 
sensitivity 9. In view of the fact that PYY3-36 inhibits NPY- and activates POMC 
neuronal activity, we wondered whether it could improve insulin sensitivity “directly” 
(i.e. through a mechanism independent of food intake and body weight). To address 
this question, we infused PYY3-36 intravenously and quantified its acute effects on 
glucose and fatty acid flux during a hyperinsulinemic euglycemic clamp in mice 
without access to food during the experiment. 
 
Methods 
Animals. Male C57BL/6J mice were housed in a temperature-controlled room on a 
12-hour light-dark cycle and were fed a high fat diet (43 energy% fat derived from 
bovine lard) with free access to water for 2 weeks to induce insulin resistance. All 
animal experiments were performed in accordance with the regulations of Dutch law 
on animal welfare and the institutional ethics committee for animal procedures 
approved the protocol. 
Hyperinsulinemic euglycemic clamp. Thirty-six mice were fasted overnight with 
food withdrawn at 05.00 pm the day prior to the study. The next day, 
hyperinsulinemic euglycemic clamps were performed as described earlier 10. PYY or 
vehicle was administered as a primed (0.15 µg) continuous (0.25 µg/h) intravenous 
(i.v.) infusion during the whole experiment (basal and hyperinsulinemic period). In 
one series of experiments glucose turnover was quantified and in another series FFA 
turnover was determined. First, basal rates of glucose or FFA turnover were 
measured by giving a primed (p) continuous (c) infusion of 3H-glucose (p: 0.7 µCi, c: 
1.2 µCi/h) (Amersham, Little Chalfont, U.K.) or 14C-palmitate (p: 1.8 µCi, c: 3 µCi/h) 
(Amersham, Little Chalfont, U.K) respectively for 80 min. Subsequently, insulin was 
administered in a primed (4.1 mU) continuous (6.8 mU/h) i.v. infusion for 2 to 3 hours 
to attain steady state circulating insulin levels of ~6 ng/ml. A variable infusion of 
12.5% D-glucose was used to maintain euglycemia (measured at 10 min intervals via 
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tail bleeding, Freestyle, TheraSense, Disetronic Medical Systems BV, Vianen, The 
Netherlands). Blood samples (75 µl) were taken during the basal period (after 60 and 
80 minutes) and during the clamp period (when glucose levels were stable and 20 
and 40 minutes later) for determination of plasma glucose, FFA and insulin 
concentrations and 3H-glucose and 14C-palmitate specific activities.  
To assess insulin-mediated glucose uptake in individual tissues, 2-deoxy-D-
[3H] glucose (2-[3H]DG; Amersham, Little Chalfont, UK) was administered as a bolus 
(1µCi), 40 minutes before the end of the clamp experiments in which FFA turnover 
was measured. At the end of the clamp, mice were sacrificed and muscle and 
adipose tissue were isolated and frozen in liquid nitrogen for subsequent analysis. 
Analytical procedures. Plasma levels of glucose and FFA were determined using 
commercially available kits (Instruchemie, Delfzijl, The Netherlands and Wako, 
Neuss, Germany). Plasma insulin and PYY3-36 concentrations were measured by a 
mouse insulin ELISA and PYY3-36 RIA (Alpco, Windham, NH, USA; Phoenix 
pharmaceuticals, Belmont, CA, USA). Total plasma 3H-glucose was determined in 
7.5 µl plasma and in supernatants after trichloroacetic acid (20%) precipitation and 
water evaporation to eliminate tritiated water. Total plasma 14C-palmitate was 
determined in 7.5 µl plasma after extraction of lipids by a modification of Bligh and 
Dyer’s method 11. Briefly, 7.5 µl plasma was dried and resolved in 100 µl water. Then 
1.1 ml demi-water and 4.5 ml methanol:chloroform (2:1) was added and mixed 
thoroughly, after which 1.5 ml chloroform was added and mixed and finally, 1.5 ml 
demi-water was added and mixed. After centrifugation, the chloroform layer was 
collected and the FFA fraction was separated from other lipid components by thin-
layer chromatography (TLC) on silica gel plates.  
Tissue analysis. For determination of tissue 2-DG uptake, the homogenate of 
muscle and adipose tissue was boiled and the supernatant was subjected to an ion-
exchange column to separate 2-DG-6-P from 2-DG as described previously 10;12;13. 
Calculations. Turnover rates of glucose and FFA (µmol/min/kg) were calculated 
during the basal period and in steady-state clamp conditions as the rate of tracer 
infusion (dpm/min) divided by the plasma specific activity of 3H-glucose or 14C-
palmitate (dpm/µmol). The ratio was corrected for body weight. EGP was calculated 
as the difference between the tracer-derived rate of glucose appearance and the 
glucose infusion rate. 
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Tissue-specific glucose uptake in muscle and adipose tissue was calculated from 
tissue 2-DG content, corrected for plasma specific activity and expressed as µmol 
per gram of tissue.   
Statistical analysis. Differences between groups were determined by Mann-Whitney 
non-parametric test for 2 independent samples. A P-value < 0.05 was considered 
statistically significant. All values shown represent mean ± SD. 
 
Results 
Animals. Mice were 16-18 weeks old during the experiments. Body weight was 23.3 
± 1.2 gram in the control group and 22.8 ± 1.4 gram in the PYY group. 
Plasma parameters. Plasma glucose, FFA, insulin and PYY3-36 concentrations in 
basal and hyperinsulinemic conditions are shown in table 1. In the basal state, 
plasma parameters did not differ between PYY- and vehicle-infused animals, except 
for the plasma PYY3-36 concentration. In steady state clamp conditions, plasma 
insulin and glucose concentrations were similar in both groups. Hyperinsulinemia 
suppressed FFA levels to a similar extent in PYY- and vehicle-infused mice.  
 
Table 1. Plasma parameters in overnight fasted mice that received an i.v.-infusion of PYY or vehicle 
under basal or hyperinsulinemic conditions. Values represent mean ± SD for at least 7 mice per group.  
 
  Basal   Hyperinsulinemic  
 Vehicle PYY Vehicle PYY 
Glucose (mmol/l) 4.9 ± 0.6 5.0 ± 0.6 9.0 ± 0.9 9.2 ± 2.0 
FFA (mmol/l) 0.9 ± 0.2 1.0 ± 0.2 0.4 ± 0.1 0.5 ± 0.1 
Insulin (ng/ml) 0.3 ± 0.1 0.3 ± 0.1 5.2 ± 2.9 6.7 ± 2.7 
PYY3-36 (pg/µl) < 1 3.8 ± 0.7 < 1 3.2 ± 0.7 
  
 
Glucose turnover. In the basal condition, glucose disposal was similar in PYY- and 
vehicle-infused mice (39,5 ± 10.9 vs. 45.9 ± 12.6 µmol/min/kg, respectively; P=0.19, 
Figure 1a). The rate of glucose infusion necessary to maintain euglycemia during 
insulin infusion was significantly higher in PYY-infused mice than in vehicle-infused 
animals (89.1 ± 7.1 vs. 50.9 ± 13.6 µmol/min/kg, P=0.001), indicating that i.v. PYY3-36 
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administration acutely enhances insulin sensitivity. Hyperinsulinemia increased 
glucose disposal in both groups. However, the disposal rate was significantly higher 
in PYY-infused animals compared with vehicle-infused controls (103.8 ± 10.9 vs. 76.1 
± 11.4 µmol/min/kg, respectively, P=0.001, Figure 1a). In contrast, endogenous 
glucose production (EGP), which was similar in PYY and vehicle treated mice in 
basal conditions, was suppressed by insulin to the same extent in both groups. (by 













Figure 1. Glucose disposal (a) and endogenous glucose production (b) in overnight fasted mice 
before (basal) and during (hyperinsulinemic) a hyperinsulinemic euglycemic clamp. Prior to and during 
insulin infusion the animals received an i.v.-infusion of PYY or vehicle. Values represent mean ± SD 
for at least 7 mice per group. *P<0.01 vs. vehicle. 
 
Tissue-specific glucose uptake. Insulin-mediated 2-deoxy-glucose uptake in 
muscle and adipose tissue was greater in PYY-treated animals, but the difference 
with controls did not reach statistical significance in adipose tissue (muscle: 2.1 ± 0.5 
vs. 1.5 ± 0.5 µmol/ g tissue, P=0.049; adipose tissue: 0.8 ± 0.4 vs. 0.4 ± 0.3 µmol/ g 
tissue; P=0.08, Figure 2). 
FFA turnover. Basal free fatty acid turnover  (38.0 ± 14.2 vs. 42.3 ± 9.9 µmol/min/kg) 
was not different between PYY- and vehicle-infused animals and was suppressed to 
a similar extent by insulin in both groups (22.4 ± 12.3 vs. 21.3 ± 10.9 µmol/min/kg in 




























































Figure 2. Muscle-specific (a) and adipose tissue-specific (b) glucose uptake under hyperinsulinemic 
conditions in overnight fasted mice that received an i.v.-infusion of PYY or vehicle. Values represent 





























Here we show that intravenous PYY3-36 administration acutely reinforces insulin 
action on glucose disposal in overnight fasted mice maintained on a high fat diet. In 
contrast, PYY3-36 does not appear to impact the effect of insulin on endogenous 
glucose production or FFA metabolism in this experimental context.  
PYY3-36 clearly enhanced insulin-induced glucose disposal as determined by 











Figure 3. Free fatty acids (FFA) turnover in 
overnight fasted mice before (basal) and 
during (hyperinsulinemic) a hyperinsulinemic 
euglycemic clamp. Prior to and during insulin 
infusion the animals received an i.v.-infusion 
of PYY or vehicle. Values represent mean ± 
SD for at least 9 mice per group.  
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in hyperinsulinemic conditions was higher during PYY3-36 infusion, albeit the 
difference with control attained statistical significance only for muscle. In contrast, 
PYY3-36 did not significantly impact the capacity of insulin to inhibit endogenous 
glucose production. Insulin action on FFA metabolism was not affected by PYY3-36 
either, as indicated by similar fatty acid turnover rates during hyperinsulinemia in 
PYY3-36 and saline infused animals. In light of the current experimental context, these 
data suggest that PYY3-36 reinforces the impact of insulin on glucose disposal 
through a mechanism that is independent of food intake and body weight. In contrast, 
it appears to leave insulin action on glucose production and FFA turnover largely 
unaffected. 
The plasma PYY3-36 concentration rose to 3.2 ± 0.7 pg/µl in response to PYY 
infusion. Relatively few studies have looked at the physiology of circulating PYY3-36 in 
rodents. According to a recent paper by Batterham et al.3, postprandial PYY3-36 
concentrations amount to 112 pmol/l (~0.4 pg/µl) in freely feeding rats. In a study by 
Lee et al 14 plasma PYY levels in fasting mice were 0.18 pg/µl, which accords with 
our data (table 1). We are not aware of any study measuring postprandial PYY3-36 
concentrations in mice. Thus, the dose of PYY3-36 we administered may have induced 
supraphysiological PYY3-36 levels. Therefore, our data do not allow a definitive 
inference as to whether the postprandial rise of circulating PYY3-36 can reinforce 
insulin action.  
 Postprandial PYY3-36 release is decreased in obese compared with lean 
subjects and circulating levels correlate negatively with body mass index. 
Conversely, intravenous PYY3-36 infusion significantly reduces food intake in humans 
15 and repeated administration of PYY3-36 attenuates weight gain in rodents 3. These 
findings suggest that diminished PYY3-36 release may contribute to the pathogenesis 
of obesity in animals and man. The observations presented here allow us to 
hypothesize that low circulating PYY3-36 levels may also compromise insulin action in 
obese subjects. Moreover, perhaps even more important, the data suggest that 
PYY3-36 or synthetic analogues of this peptide may be useful tools in the clinical 
management of obesity and insulin resistance. 
 It remains to be established whether PYY3-36 acts through hypothalamic neural 
circuits (in analogy of the mechanism guiding its effects on appetite) to enhance 
insulin-mediated glucose disposal. As PYY3-36 is a high affinity agonist to the Y2R 2 
and the distribution of this receptor subtype is largely confined to the central nervous 
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system (particularly the arcuate nucleus of the hypothalamus) 16, it is most likely that 
PYY3-36 modulates insulin action by activation of Y2R in the brain. As alluded to 
earlier, Y2R signaling inhibits NPY neuronal activity in the arcuate nucleus of the 
hypothalamus and thereby activates adjacent POMC neurons 3. Hypothalamic 
overexpression of NPY induces obesity and insulin resistance in mice 7;8, whereas 
activation of melanocortin receptor subtypes 3 and 4 in the brain enhances insulin 
sensitivity 9. Thus, the present data are in keeping with the contention that PYY3-36 
modulates insulin action via hypothalamic Y2R. The downstream mechanisms that 
actuate the effects of hypothalamic neuronal circuits on muscle and adipose tissue 
remain to be fully elucidated. At this point, vagotomy was shown to prevent the 
hyperinsulinemic effects of NPY, which suggests that the autonomic nervous system 
may be involved 17. Also, adrenalectomy prevents the obesity syndrome produced by 
chronic central NPY infusion and reverses the obese phenotype in leptin-deficient 
ob/ob mice 18;19, indicating that the pituitary-adrenal ensemble may also serve as a 
second messenger. Thus, neural and/or endocrine mechanistic routes may convey 
signals from hypothalamic nuclei to peripheral tissues to orchestrate energy balance 
and fuel flux. It is conceivable that similar routes partake in the control of insulin 
action by PYY3-36. 
 In conclusion, PYY3-36 reinforces insulin action in mice maintained on a high 
fat diet through a mechanism that is independent of food intake and body weight. In 
this context, PYY3-36 appears to predominantly impact insulin-mediated glucose 
disposal, whereas it leaves insulin action on glucose production largely unaffected. 
These novel data suggest that PYY3-36 or synthetic analogues of this peptide may be 
valuable assets to our armamentarium of drugs designed to battle insulin resistance 
and type 2 diabetes mellitus. 
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Abstract 
PYY3-36 is a gut-derived hormone, that acts on hypothalamic nuclei to modulate 
energy metabolism. We recently showed, that PYY3-36 acutely reinforces insulin 
action on glucose disposal in insulin resistant mice. Because the long-term effects of 
PYY3-36 on insulin sensitivity are still unknown, we examined the effects of chronic 
PYY3-36 administration (2.5 µg/day s.c. for 7 days) on glucose turnover during a 
hyperinsulinemic-euglycemic clamp in C57BL6 mice maintained on a high fat diet for 
16 weeks before the experiment. In addition, metabolic efficacy of continuous vs. 
intermittent administration of PYY3-36 was evaluated. Under hyperinsulinemic 
conditions, glucose disposal was significantly increased in PYY3-36 treated mice vs. 
vehicle-treated mice (78.8 ± 13.3 vs. 63.4 ± 15.5 µmol/min/kg, respectively, 
P=0.012). Tissue specific glucose uptake was significantly increased in adipose 
tissue (0.5 ± 0.2 vs. 0.2 ± 0.1 µmol/ g tissue; P=0.006), but not in muscle (2.2 ± 1.4 
vs. 1.6 ± 0.8 µmol/ g tissue for PYY3-36 and vehicle-treated animals, respectively, 
P=0.38) of PYY3-36 treated animals. In contrast, insulin action on endogenous 
glucose production was not significantly affected. Furthermore, none of these 
metabolic parameters were affected by the mode of PYY3-36 administration 
(continuous or intermittent). 
  In conclusion, chronic PYY3-36 administration enhances the ability of insulin to 
promote glucose disposal, whereas it does not significantly affect endogenous 
glucose production in C57BL6 mice maintained on a high fat diet for 16 weeks. In 
addition, this study shows that continuous and intermittent administration are equally 
effective in this respect.  
 
Introduction 
The metabolic syndrome comprises a cluster of anomalies that increase the risk of 
cardiovascular disease and type 2 diabetes mellitus: hyperglycemia, abdominal 
obesity, hypertriglyceridemia, hypertension and low levels of high-density lipoprotein 
(HDL) cholesterol 1-3. Insulin resistance may underlie the majority of these 
pathologies 4 and therapies that effectively reinforce insulin action may therefore 
ameliorate the risk profile of metabolic syndrome patients 5;6. 
Diet-induced obese, insulin resistant C57BL6-mice have increased levels of 
neuropeptide Y (NPY) and decreased levels of pro-opiomelanocortin (POMC) in 
66
Chapter 5   
66 
hypothalamic nuclei 7-9. These features of hypothalamic neural circuits may be 
involved in the pathogenesis of the metabolic syndrome, as intracerebroventricular 
(icv) administration of NPY or antagonists of POMC induce insulin resistance 10-13. 
Therefore, antagonists of NPY and/or agonists of POMC signalling may be useful 
tools in the clinical management of this syndrome. Peptide YY3-36 (PYY3-36) is 
released in response to food intake by L-cells in the distal gastrointestinal tract. It 
acts via Y2 receptors on NPY neurons in the arcuate nucleus to inhibit NPY neuronal 
activity and thereby activates adjacent POMC neurons 14;15. We recently found that 
PYY3-36 administration acutely reinforces insulin action on glucose disposal through a 
mechanism that is independent of food intake and body weight 16. This finding 
suggests that PYY3-36 may be used as a therapeutic tool in the clinical management 
of insulin resistance and the metabolic syndrome. However, the metabolic effects of 
long-term PYY3-36 administration are currently unknown, and waning of early impact 
may occur during chronic treatment through down regulation of receptor expression 
or function 17;18. Therefore, the aim of this study was to investigate the long-term 
effects of PYY3-36 on insulin action by administering PYY3-36 subcutaneously for 7 
days in mice fed a high-fat diet, and quantifying the effects on glucose production 
and disposal during a hyperinsulinemic euglycemic clamp study. As the physiology of 
PYY3-36 entails intermittent release in response to food intake, we also examined 
whether continuous and intermittent administration of PYY3-36 impact glucose 
metabolism differentially in this experimental context.  
 
Research designs and methods 
Animals. Male C57BL6 mice were housed in a temperature-controlled room on a 12-
hour light-dark cycle and were fed a high fat diet (43 energy% fat derived from bovine 
lard) with free access to water for 16 weeks to induce insulin resistance. After 15 
weeks of high fat diet, osmotic minipumps (Alzet minipump, model 2001, Charles 
River, Maastricht, The Netherlands) were placed subcutaneously in the back region 
under light isoflurane anesthesia. All mice received a saline (n = 15) or PYY3-36 (2.5 
µg/day, n = 5) infusion via the osmotic minipump at a rate of 0.5 µl/h for 7 days. In 
addition, daily subcutaneous injections (50 µl at 09.00 am) of saline or PYY3-36 (2.5 
µg) were given, where mice receiving continuous PYY3-36 treatment were additionally 
injected with saline, and mice receiving saline by minipump were assigned to receive 
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either saline (n = 8) or PYY3-36 (n = 7) by injection. Thus, glucose kinetics were 
determined in 2 experimental groups: 1) receiving saline and 2) receiving PYY3-36, 
where PYY3-36 was administered continuously by minipump or intermittently by daily 
subcutaneous injection.  All animal experiments were performed in accordance with 
the regulations of Dutch law on animal welfare and the institutional ethics committee 
for animal procedures approved the protocol. 
Hyperinsulinemic euglycemic clamp. Mice were fasted overnight with food 
withdrawn at 05.00 pm the day prior to the study. The next day, hyperinsulinemic 
euglycemic clamps were performed as described earlier 19. First, basal rates of 
glucose turnover were measured by giving a primed (0.7 µCi) continuous (1.2 µCi/h) 
infusion of 14C-glucose (Amersham, Little Chalfont, U.K.) for 80 min. Subsequently, 
insulin was administered in a primed (4.1 mU) continuous (6.8 mU/h) i.v. infusion for 
2 to 3 hours to attain steady state circulating insulin levels of ~3.5 ng/ml. A variable 
infusion of 12.5% D-glucose was used to maintain euglycemia (measured at 10 min 
intervals via tail bleeding, Freestyle, TheraSense, Disetronic Medical Systems BV, 
Vianen, The Netherlands). Blood samples (75 µl) were taken during the basal period 
(after 60 and 80 minutes) and during the clamp period (when glucose levels were 
stable and 20 and 40 minutes later) for determination of plasma glucose, FFA, insulin 
and PYY3-36 concentrations and 14C-glucose specific activities.  
To assess insulin-mediated glucose uptake in individual tissues, 2-deoxy-D-
[3H] glucose (2-[3H]DG; Amersham, Little Chalfont, UK) was administered as a bolus 
(1µCi), 40 minutes before the end of the clamp experiments. At the end of the clamp, 
mice were sacrificed and muscle and adipose tissue were isolated and frozen in 
liquid nitrogen for subsequent analysis. 
Analytical procedures. Plasma levels of glucose and FFA were determined using 
commercially available kits (Instruchemie, Delfzijl, The Netherlands and Wako, 
Neuss, Germany). Plasma insulin and PYY3-36 concentrations were measured by a 
mouse insulin ELISA and PYY3-36 RIA (Mercodia, Uppsala, Sweden; Phoenix 
pharmaceuticals, Belmont, CA, USA; sensitivity of 1 pg/µl for the PYY3-36 RIA). Total 
plasma 14C-glucose was determined in 7.5 µl plasma and in supernatants after 
trichloroacetic acid (20%) precipitation and water evaporation to eliminate tritiated 
water.  
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Tissue analysis. For determination of tissue 2-DG uptake, the homogenate of 
muscle and adipose tissue was boiled and the supernatant was subjected to an ion-
exchange column to separate 2-DG-6-P from 2-DG as described previously 19-21. 
Calculations. Turnover rates of glucose (µmol/min/kg) were calculated during the 
basal period and in steady-state clamp conditions as the rate of tracer infusion 
(dpm/min) divided by the plasma specific activity of 14C-glucose (dpm/µmol). The 
ratio was corrected for body weight. EGP was calculated as the difference between 
the tracer-derived rate of glucose appearance and the glucose infusion rate. 
Tissue-specific glucose uptake in muscle and adipose tissue was calculated 
from tissue 2-DG content, corrected for plasma specific activity and expressed as 
µmol per gram of tissue.   
Statistical analysis. Differences between groups were determined by Mann-Whitney 
non-parametric test for 2 independent samples. A P-value < 0.05 was considered 
statistically significant. All values shown represent means ± SD. 
 
Results 
Animals. Body weight did not differ between PYY3-36 and vehicle-infused animals 
(after 7 days of PYY3-36/saline administration: 28.0 ± 3.7 gram in the PYY3-36 group 
and 28.3 ± 1.5 gram in the control group, P=0.68). Overnight food intake was 
measured at day 2 and day 5 of PYY3-36/saline administration and was similar in both 
groups (day 2: 2.37 ± 0.68 vs. 2.32 ± 0.33 gram, P=0.96; day 5: 2.76 ± 0.54 vs. 2.75 
± 0.43 gram, P=0.97 in PYY3-36 and vehicle-treated animals, respectively). 
Furthermore, body weight and overnight food intake was not different in groups 
receiving continuous or intermittent PYY3-36 treatment (body weight: 29.5 ± 3.9 vs. 
26.9 ± 3.4 gram, P=0.20; food intake day 2: 2.14 ± 0.98 vs. 2.48 ± 0.56 gram, 
P=0.38; day 5: 2.53 ± 0.69 vs. 2.92 ± 0.39 gram, P=0.27 for continuous and 
intermittent administration, respectively). 
Plasma parameters. Plasma glucose, FFA, and insulin concentrations in basal and 
hyperinsulinemic conditions are shown in table 1. Plasma glucose and insulin 
concentrations did not differ between vehicle and PYY3-36 treated animals under 
basal and steady state clamp conditions. Furthermore, continuous and intermittent 
PYY3-36 administration had similar impact on these parameters, except for the plasma 
glucose levels under basal conditions, which were slightly but significantly higher in 
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the group that received continuous PYY3-36 administration (basal glucose: 9.3 ± 0.9 
vs. 7.7 ± 1.5 mmol/l, P=0.048; hyperinsulinemic glucose: 9.9 ± 0.8 vs. 9.1 ± 0.6 
mmol/l, P=0.073; basal insulin: 0.9 ± 0.4 vs. 0.5 ± 0.3 ng/ml, P=0.073; 
hyperinsulinemic insulin: 3.9 ± 1.0 vs. 3.4 ± 0.6 ng/ml, P=0.43). Plasma FFA 
concentrations were slightly, but significantly, lower in PYY3-36 treated mice in basal 
(P=0.025) and steady state clamp (P=0.031) conditions, where continuous and 
intermittent PYY3-36 administration did not have differential effects (basal FFA: 0.9 ± 
0.3 vs. 0.9 ± 0.1 mmol/l, respectively, P=0.76; hyperinsulinemic FFA: 0.5 ± 0.1 vs. 0.4 
± 0.1 mmol/l, respectively, P=0.073). Plasma PYY3-36 concentrations in basal and 
hyperinsulinemic conditions were below the detection level in all groups (<1 pg/µl), 
except for the basal condition of the mice that received intermittent PYY3-36 
administration (3.7 ± 0.8 pg/µl). 
 
Table 1. Plasma parameters under basal or hyperinsulinemic conditions in overnight fasted mice that 
received PYY3-36 (n=12) or vehicle (n=8) for 7 days. Data are the means ± SD. * <0.05 vs. vehicle. 
 
Glucose turnover. In basal conditions, glucose disposal was similar in PYY3-36 and 
vehicle-treated mice (52.0 ± 10.5 vs. 50.4 ± 10.4 µmol/min/kg, respectively, P=0.68). 
The rate of glucose infusion necessary to maintain euglycemia during insulin infusion 
was significantly higher in PYY3-36 treated mice than in vehicle-treated animals (54.0 
± 11.4 vs. 33.4 ± 11.6 µmol/min/kg, P=0.000), indicating that chronic PYY3-36 
administration enhances whole body insulin sensitivity. Continuous and intermittent 
administration of PYY3-36 had similar effects on the glucose infusion rate (54.7 ± 9.2 
vs. 53.6 ± 10.2 µmol/min/kg, respectively, P=0.27). Hyperinsulinemia increased 
glucose disposal in both groups. However, the disposal rate was significantly higher 
  Basal   Hyperinsulinemic  
 Vehicle PYY3-36 Vehicle PYY3-36 
Glucose (mmol/l) 7.7 ± 1.3 8.4 ± 1.5 8.4 ± 1.2 9.4 ± 0.8 
FFA (mmol/l) 1.1 ± 0.2 0.9 ± 0.2 0.6 ± 0.1 0.5 ± 0.1 
Insulin (ng/ml) 0.7 ± 0.3 0.7 ± 0.4 3.2 ± 0.9 3.6 ± 0.8 
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in PYY3-36 treated animals compared with vehicle-treated controls (78.8 ± 13.3 vs. 
63.4 ± 15.5 µmol/min/kg, respectively, P=0.012, Figure 1a) and was similar in 
animals treated by continuous and intermittent administration (81.2 ± 13.8 vs. 77.1 ± 
13.7 µmol/min/kg, respectively, P=0.64).  
Endogenous glucose production was similar in PYY3-36 and vehicle-treated 
mice in basal conditions and was suppressed by insulin to the same extent in both 
groups (by 54 ± 18 vs. 40 ± 26% from basal in PYY3-36 vs. vehicle treated groups, 
respectively; P=0.27, Figure 1b), where percent inhibition did not differ between 
animals receiving continuous or intermittent PYY3-36 treatment. (52 ± 25 vs. 55 ± 12% 
































































Figure 1. Insulin mediated glucose disposal (a) and inhibition of endogenous glucose production 
(EGP) by insulin (b) in overnight fasted mice before (basal) and during (hyperinsulinemic) a 
hyperinsulinemic euglycemic clamp study. Prior to the clamp experiment the animals received PYY3-36 
(n=12) or vehicle (n=8) for 7 days. Values represent the means ± SD. *P<0.05 vs. vehicle. 
 
Tissue-specific glucose uptake. Insulin-mediated 2-deoxy-glucose uptake was 
measured in muscle and adipose tissue. In muscle, 2-deoxy-glucose was similar in 
both groups (2.2 ± 1.4 vs. 1.6 ± 0.8 µmol/ g tissue for PYY3-36 and vehicle-treated 
animals, respectively, P=0.38). In adipose tissue 2-deoxy-glucose uptake was 
significantly increased in PYY3-36 treated animals compared with vehicle treated mice 
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Figure 2. Muscle-specific (a) and adipose tissue-specific (b) glucose uptake under hyperinsulinemic 
conditions in overnight fasted mice that received PYY3-36 (n=11) or vehicle (n=7) for 7 days. Values 
represent the means ± SD. *P<0.05 vs. vehicle. 
 
Discussion 
Here we show that chronic PYY3-36 administration improves whole body insulin 
sensitivity of glucose metabolism in C57BL6 mice maintained on a high fat diet for 16 
weeks. In particular, PYY3-36 treatment enhances the ability of insulin to promote 
glucose disposal via mechanistic routes that are independent of food intake or body 
weight. In addition, this study documents that continuous and intermittent 
administration of PYY3-36 reinforce insulin action to a similar extent. 
These data corroborate our previous findings, which unveil similar acute 
effects of  PYY3-36 administration on insulin action 16, and support the emerging 
concept of neural circuits controlling fuel flux, independent of their impact on food 
intake and body weight. In addition, our data indicate that the effects of PYY3-36 on 
glucose metabolism do not wane during chronic treatment, which suggests that this 
peptide may be a novel asset in the battle against insulin resistance and the 
metabolic syndrome.  
Although PYY3-36 enhanced insulin-induced glucose disposal, it did not 
significantly affect the ability of insulin to inhibit endogenous glucose production. 
Nonetheless, we can not exclude the possibility that the experimental group size may 
have limited the statistical power necessary to detect a subtle influence of PYY3-36 on 
hepatic glucose metabolism. Alternatively, PYY3-36 exerts differential, tissue specific, 
effects on insulin action.  
A B 
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The mechanism by which PYY3-36 affects insulin-mediated glucose metabolism 
remains to be elucidated. Perhaps, PYY3-36 modulates insulin action via the 
hypothalamic Y2 receptor, in analogy with the mechanism guiding its effects on 
appetite. Y2-receptor mediated inhibition of NPY and stimulation of POMC neuronal 
activity by PYY3-36 potentially reinforces insulin action on glucose metabolism indeed 
10;11;13.  
Circulating PYY3-36 levels in fasting conditions remained below the level of 
detection (< 1 pg/µl) during continuous treatment, and rose to 3.7 ± 0.8 pg/µl 
approximately one hour after i.p injection. During hyperinsulinemia (3-3.5 hours after 
injection), PYY3-36 levels were undetectable by our assay in all animals. Thus, in spite 
of the fact that continuous PYY3-36 treatment did not produce measurable plasma 
concentrations and intermittent administration induced a merely transitory increase of 
circulating PYY3-36, both treatments significantly facilitated insulin mediated glucose 
disposal in high fat fed animals. Relatively few papers report plasma PYY3-36 
concentrations in rodents. Postprandial levels may be in the range of 112 pmol/L (∼ 
0.4 pg/µl) and 0.18 pg/µl in freely feeding normal weight rats and mice respectively 
14;22, whereas fasting levels are considerably lower, as PYY3-36 is primarily released 
in response to food intake 14;23. Plasma PYY3-36 concentrations in high fat fed mice 
are unknown, but may be significantly reduced, as obese humans have clearly 
diminished circulating PYY3-36 levels 24. Taken together, our data suggest, that even 
a relatively low dose of PYY3-36 (in view of the low circulating PYY3-36 levels during 
treatment) can reinforce insulin action. Further dose-response experiments are 
warranted to evaluate the potential efficacy of PYY3-36 in the treatment of the 
metabolic syndrome. 
Food intake and body weight were not affected by PYY3-36 administration in 
our study. These findings agree with data from Challis et al., indicating that 7 days of 
PYY3-36 administration did not affect food intake and body weight in POMC-/- and wild 
type mice 25. In contrast, Batterham et al. reported that PYY3-36 acutely inhibits food 
intake 14, an observation that could not be reproduced by Tschöp and coworkers 26;27. 
To take this issue further, we compared the acute effects of a single intraperitoneal 
(2.5 µg) injection of PYY3-36 (n = 8) or vehicle (n = 8) at 09.00 am on food intake in 
our animals, and found that cumulative food intake in 4 hours after injection was 
significantly inhibited by 21% in overnight fasted mice (P=0.028), whereas 
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subsequent feeding over 24 hours was not affected by PYY3-36. These data suggest 
that this dose of PYY3-36 has a short-term inhibitory impact on food intake in overnight 
fasted C57BL6 mice, whereas consumption over 24 hours is not affected, probably 
as a result of a rebound compensatory increase of appetite 14;15. 
 In conclusion, the present study shows that chronic PYY3-36 administration 
reinforces insulin action on glucose disposal in mice maintained on a high fat diet, 
whereas it also tends to enhance the ability of insulin to suppress endogenous 
glucose production. These observations suggest that PYY3-36 or potential analogues 
may be a useful treatment for insulin resistance and the metabolic syndrome. 
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Abstract 
Many obese humans appear to be both insulin- and leptin resistant. Since leptin may 
impact glucose metabolism directly, it is conceivable that lack of leptin signal 
transduction critically contributes to insulin resistance in these individuals. 
Furthermore, at this time, it remains unclear if leptin affects glucose metabolism via 
peripheral and/or central mechanistic routes. To explore the contribution of cerebral 
leptin deficiency to insulin resistance in leptin deficient ob/ob mice, we infused leptin 
i.c.v. in ob/ob mice. To also evaluate the impact of adiposity on insulin action in these 
animals, another group of young ob/ob animals were subjected to severe calorie 
restriction, so that their body weight became similar to that of wild type mice. 
Hyperinsulinemic euglycemic clamps and isotope dilution techniques were used to 
determine insulin sensitivity of hepatic glucose production (HGP) and disposal (GD). 
Leptin infusion (i.c.v., 2.5 µg/h for 3 hours) acutely increased both the hepatic insulin 
sensitivity index and glucose disposal index (9.1±2.4. vs. 5.0±2.7 %·nmol-1 and 
25.6±5.6. vs. 13.6±4.8 µmol·min-1·kg-1·nmol-1, respectively; P<0.05 for both 
comparisons) in ob/ob mice. Furthermore, i.c.v. leptin administration acutely reduced 
circulating insulin levels during continuous insulin infusion. 
Food restriction barely affected body composition although it profoundly 
curtailed body weight. Insulin suppressed HGP clearly more in the lean ob/ob mice 
than in their obese counterparts, but its impact remained less than in wild-type mice 
(% suppression: 11.8±8.9 vs. 1.3±1.1 vs. 56.6±13.0 %·nmol-1, respectively; P<0.05). 
The glucose disposal index of lean ob/ob mice was also in between that of obese 
ob/ob and lean wild-types (37.5±21.4 vs. 25.1±14.6 vs. 59.6±17.3 µmol·min-1·kg-
1·nmol-1, respectively; P<0.05 wild-type mice vs. ob/ob mice). In conclusion, leptin 
deficiency per se is not just responsible for hyperphagia and obesity in ob/ob mice, 
but critically determines body composition, insulin action and insulin clearance from 
the circulation in these animals. The data suggest that leptin resistance in obese 




Leptin conveys signals pertaining to the size of bodily energy stores to the brain, 
where it orchestrates behavioral and metabolic adaptations meant to maintain energy 
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balance in the face of environmental fluctuations in nutrient availability 1-3. Leptin may 
also affect body composition, as suggested by the fact that it specifically reduces fat 
mass (leaving lean body mass untouched) in rodents 4. 
Leptin deficiency produces severe obesity, insulin resistance and impaired 
glucose tolerance in ob/ob mice 5;6. The ratio of adipose over lean tissue is 
significantly elevated in these animals 7. Since in vivo measures of insulin sensitivity 
correlate strongly with total and regional fat mass in animals and humans 8;9, it is 
tempting to attribute at least part of  the metabolic anomalies of ob/ob mice to their 
altered body composition. However, there is also evidence to suggest that leptin 
impacts glucose metabolism independently of its effects on food intake and body 
weight. Accordingly, intraperitoneal administration of leptin acutely reduces glycemia 
and insulinemia and restores glucose tolerance without affecting body weight in 
ob/ob mice. Injection of a low dose of leptin into the ventromedial hypothalamus of 
lean rats promotes basal (insulin independent) glucose uptake in various tissues, 
suggesting that the central nervous system is a critical target of leptin in the control of 
glucose metabolism 10;11. Leptin deficient ob/ob mice are an ideal model to study the 
(metabolic) impact of leptin, as exogenously administered leptin inevitably competes 
with endogenous peptide in wild-type animals. We therefore used ob/ob mice to 
evaluate the effects of i.c.v. leptin infusion on insulin sensitivity. To determine the 
simultaneous impact of the obese phenotype of these animals on insulin action, we 
also subjected young ob/ob animals to severe calorie restriction, so that their body 
weight became similar to that of wild type mice. In both experimental settings, 
hyperinsulinemic euglycemic clamps and isotope dilution techniques were used as 
measures of in vivo insulin action on glucose metabolism. 
 
Research designs and methods 
Animals. Wild-type and ob/ob mice were obtained from our breeding colony of 
C57BL6 ob+/- mice. Mice were individually housed in a temperature-controlled room 
on a 12:12h light-dark cycle and were fed a standard mouse chow diet with free 
access to water. All animal experiments were performed in accordance with the 
regulations of Dutch law on animal welfare and the institutional ethics committee for 
animal procedures approved the protocol. 
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I.c.v. leptin experiment. Male ob/ob mice were anesthetized with 0.5 mg/kg 
Medetomidine (Pfizer, Capelle a/d IJssel, The Netherlands), 5 mg/kg Midazolam 
(Roche, Mijdrecht, The Netherlands) and 0.05 mg/kg Fentanyl (Janssen-Cilag, 
Tilburg, The Netherlands). A 25-gauge guide cannula was stereotaxically implanted 
into the left lateral ventricle using the following coordinates from Bregma: 0.46 mm 
posterior, 1.0 mm lateral and 2.2 mm ventral 12. The guide cannula was secured with 
dental cement (Oral Hygiene Center BV, Amersfoort, The Netherlands) to the skull 
surface. After a recovery period of 1 week, adequate placement of the cannulae was 
tested with the feeding response to an i.c.v. injection of NPY (5 µg dissolved in 1 µl of 
sterile water; Bachem, Bubendorf, Germany). After overnight fasting, a 
hyperinsulinemic euglycemic clamp experiment was performed under 6.25 mg/kg 
Acepromazine (Sanofi sante animale, Libourne Cedex, France), 6.25 mg/kg 
Midazolam (Roche, Mijdrecht, The Netherlands) and 312.5 µg/kg Fentanyl (Janssen-
Cilag, Tilburg, The Netherlands) anesthesia. During the entire experiment (basal and 
hyperinsulinemic period) leptin (1 µg/µl; Bachem, Bubendorf, Germany) or vehicle 
was infused into the left lateral ventricle at a rate of 2.5 µl/h.  
Food restriction experiment. Male and female mice were divided into the following 
experimental groups: 1) ad libitum-fed ob/ob mice, 2) ob/ob mice food restricted to 
55% of the ad libitum wild-type food intake, 3) ad libitum-fed wild-type mice. Three 
nights preceding the experiments, all groups were food restricted for two nights to 55 
% of the wild-type food intake (this was done to avoid potential bias of the results 
attributable to differences in daily caloric intake) followed by overnight fast. The next 
morning, a hyperinsulinemic euglycemic clamp was performed under 0.5 ml/kg 
Hypnorm (Janssen pharmaceutica, Beerse, Belgium) and 12.5 mg/kg Midazolam 
(Roche, Mijdrecht, The Netherlands) anesthesia.  
Hyperinsulinemic euglycemic clamp. Hyperinsulinemic clamps were performed at 
9.00 a.m. as described earlier 13;14. Basal rates of glucose turnover were determined 
by administering a primed (P) continuous (C) infusion (P: 0.8 µCi, C: 0.02 µCi/min) of 
3-3H-glucose (Amersham, Little Chalfont, U.K.). After 60 min, insulin was given as a 
prime (10 mU) followed by continuous infusion of 0.25 mU/min. A variable infusion of 
12.5% D-glucose was used to maintain euglycemia (measured at 10 min intervals via 
tail bleeding, Freestyle, TheraSense, Disetronic Medical Systems BV, Vianen, The 
Netherlands). Blood samples (60 µl) were taken at the end of the basal period and 
during the clamp (40 and 20 min before and by the end of the clamp) for 
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determination of 3-3H-glucose specific activity and plasma insulin, glucose and free 
fatty acid (FFA) concentrations. At the end of the clamp, mice were sacrificed and 
tissue samples were taken within 5 min, frozen immediately in liquid nitrogen and 
stored at –20°C for subsequent analysis. Carcasses were stored at –20 °C for body 
composition analysis.  
Analytical procedures. Plasma levels of glucose and free fatty acids (FFAs) were 
determined using commercially available enzymatic kits (Sigma, St. Louis, 
MO;Sigma, St. Louis, MO and Wako Chemicals, Neuss, Germany, respectively). 
Plasma insulin concentration was measured by radioimmunoassay (Linco Research 
Inc., St. Charles, MO). Total plasma 3-3H-glucose was determined in 7.5 µl plasma 
and in supernatants after trichloroacetic acid (20%) precipitation and water 
evaporation to eliminate tritiated water. Content of triglycerides (TG) in liver and 
muscle tissue was determined as described before 15. Briefly, 10-20 µg of tissue was 
homogenized in phosphate buffered saline (PBS) and samples were taken for 
measurement of protein content 16. Lipids were extracted and TG fraction was 
separated from the other lipid components by high performance thin layer 
chromatography (HPTLC) on silica gel plates.  
Body composition analysis. Carcasses were dehydrated at 65 °C until constant 
mass was achieved and hydrolyzed in 100 ml ethanolic potassium hydroxide (3M in 
65% ethanol). Aliquots were taken, diluted with PBS and used for determination of 
body triglyceride content (as detailed in 17;18 by enzymatic measurement of glycerol 
(Sigma, St. Louis, MO). 
Calculations. Turnover rates of glucose (µmol/min/kg) were calculated during the 
basal period and in steady-state clamp conditions as the rate of tracer infusion 
(dpm/min) divided by the plasma specific activity of 3-3H-glucose (dpm/µmol). The 
ratio was corrected for lean body mass. Hepatic glucose production (HGP) was 
calculated as the difference between the tracer-derived rate of glucose appearance 
and the glucose infusion rate. 
 The hepatic insulin sensitivity index was calculated as the ratio of the relative 
suppression of HGP during the hyperinsulinemic condition to plasma insulin levels 
during hyperinsulinemic conditions. The glucose disposal index was calculated as the 
ratio of glucose disposal to plasma insulin levels during hyperinsulinemic conditions. 
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Statistical analysis. Differences between groups were determined by Kruskall-
Wallis and Mann-Whitney nonparametric tests for independent samples. A P-value < 
0.05 was considered statistically significant. All values shown represent means ± SD. 
 
Results 
I.c.v. leptin experiment. 
Animals. Ob/ob mice were 4 months old at the time of the experiments. Body weight 
was 44.6 ± 6.7 gram in the control group and 44.7 ± 2.2 gram in the leptin group. 
Plasma parameters. Plasma glucose, FFA and insulin concentrations in basal and 
hyperinsulinemic conditions are shown in Table 1. In the basal state, plasma 
parameters did not differ between leptin- and vehicle-infused animals. In steady state 
clamp conditions, plasma glucose and FFA concentrations were similar in both 
groups. However, circulating insulin levels were significantly lower in leptin-infused 
compared to vehicle-infused animals, despite equal insulin infusion rates. 
Glucose turnover. Hyperinsulinemia suppressed the hepatic glucose production to a 
different extent in both groups. To correct for disparate insulin levels during the 
clamp, we calculated the hepatic insulin sensitivity index. This index was significantly 
higher in leptin-infused animals compared to vehicle-infused animals (9.1 ± 2.4. vs. 
5.0 ± 2.7 %·nmol-1, respectively; P<0.05, Fig. 1). 
Figure 1. Percentual inhibition of the 
endogenous glucose production 
(EGP) per nmol insulin as 
determined by hyperinsulinemic 
clamp in ob/ob mice that received an 
icv infusion of vehicle or leptin. 
Values represent the mean ± SD of 
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 Hyperinsulinemia increased glucose disposal in both groups. However, the 
glucose disposal index was significantly higher in leptin-infused- compared to 
vehicle-infused animals (25.6 ± 5.6. vs. 13.6 ± 4.8 µmol·min-1·kg-1·nmol-1, 
respectively; P<0.05, Fig. 2). 
 
 
Food restriction experiment.  
Body weight. Food restriction of ob/ob mice was initiated at the age of 2 months to 
keep them lean. However, even at 2 months, ob/ob mice were heavier than wild-type 
mice (Fig. 3). After 4 months of severe food restriction (55% of wild-type intake), 
body weight of ob/ob mice was similar to that of wild-type mice, while body weight of 




























Figure 2. Insulin mediated glucose 
disposal (Rd) per nmol insulin as 
determined by hyperinsulinemic 
euglycemic clamp in obese ob/ob 
mice that received an icv infusion of 
vehicle or leptin. Values represent 
the mean ± SD of at least 5 mice per 






















Wt Figure 3. Growth curves of ad libitum-
fed ob/ob mice (obese ob/ob), food 
restricted ob/ob mice (lean ob/ob) and 
ad libitum-fed wild-type mice (wt). At 2 
months of age ob/ob mice were food 
restricted to 55% of ad libitum wild-type 
food intake to keep them lean. Values 
represent the mean ± SD of at least 5 
mice per group.  
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Body composition. Body weight, lean body mass and the amount of water and lipid 
of lean ob/ob, obese ob/ob and wild-type mice are shown in Table 2. Although body 
weight of lean ob/ob mice was similar to that of wild-type animals, their body 
composition (lipid and lean mass expressed as percentage of body weight) was more 
like that of ad libitum fed ob/ob counterparts. Lean body mass of lean ob/ob mice 
was significantly lower than that of obese ob/ob and wild-type animals. Absolute 
amounts of TG in lean ob/ob mice were significantly higher than in wild-type -, but 
significantly lower than in obese ob/ob mice.  
Tissue TG. Hepatic TG content of lean ob/ob mice was very low as compared to 
obese ob/ob mice and similar to wild-type mice (35.3 ± 16.0, 141.7 ± 51.4, 47.1 ± 
35.3 µmol/g protein, respectively; P<0.05 lean ob/ob vs. obese ob/ob, Fig. 4A). TG 
content of muscle tended to be lower in lean ob/ob mice compared to obese ob/ob 
mice, but was significantly higher (P<0.05) compared to wild-type mice (173.2 ± 90.2, 
257.7 ± 86.7 and 59.0 ± 37.0 µmol/g protein for lean ob/ob, obese ob/ob and wild-
type mice respectively, Fig. 4B). 
Plasma parameters. Plasma glucose, FFA and insulin concentrations under basal 
and hyperinsulinemic euglycemic clamp conditions are shown in Table 3. In the basal 
state plasma parameters of lean ob/ob mice were not different from obese ob/ob 
mice. Both groups of ob/ob mice were hyperinsulinemic as compared to wild-type 
animals. Obese ob/ob mice had significantly higher plasma glucose concentrations 
as compared to wild-type mice, while circulating glucose levels in lean ob/ob mice 
were in between those in obese ob/ob and wild types.  
 In steady state clamp conditions, circulating insulin levels were significantly 
higher in ob/ob mice than in wild-type mice, despite equal insulin infusion rates. 
Glucose levels in steady state were not significantly different between lean and 
obese ob/ob mice, but glucose levels in wild-type mice were significantly lower than 
glucose levels in both groups of ob/ob mice. FFA concentrations were diminished 
during hyperinsulinemia (as compared to baseline) by ~25% in obese ob/ob, ~50% in 
lean ob/ob and ~70% in wild-type mice. 
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Figure 4. Triglyceride levels in liver (A) and muscle (B) determined in obese ob/ob, lean ob/ob and 
wild-type (wt) mice. Values represent the mean ± SD of at least 5 mice per group. * P < 0.05 vs. wt; † 




Glucose turnover. Hyperinsulinemia suppressed hepatic glucose production to a 
different extent in the three groups. The hepatic insulin sensitivity index was 
significantly higher in lean ob/ob mice compared to obese ob/ob mice, but 
significantly lower compared to wild-type mice (11.8 ± 8.9, 1.3 ± 1.1 and 56.6 ± 13.0 
%·nmol-1 for lean ob/ob, obese ob/ob and wild-type mice respectively; P<0.05, Fig. 
5). 
Insulin infusion enhanced glucose disposal in all groups. The glucose disposal 
index was significantly reduced in obese ob/ob mice as compared to wild-type, while 
the index of lean ob/ob mice was in between those of obese ob/ob and lean wild-
types (37.5 ± 21.4, 25.1 ± 14.6 and 59.6 ± 17.3 µmol·min-1·kg-1·nmol-1 for the lean 
ob/ob, obese ob/ob and wild-type mice, respectively; P<0.05 wild-type mice vs. ob/ob 
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Figure 6. Insulin mediated glucose 
disposal (Rd) per nmol insulin as 
determined by hyperinsulinemic 
euglycemic clamp in obese ob/ob, 
lean ob/ob and wild-type mice. 
Values represent the mean ± SD of 





























Figure 5. Percentual inhibition of the 
endogenous glucose production 
(EGP) per nmol insulin as 
determined by hyperinsulinemic 
clamp in obese ob/ob, lean ob/ob 
and wild-type mice. Values represent 
the mean ± SD of at least 5 mice per 
group. * P < 0.05 vs. wt.; † P < 0.05 
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Discussion 
Here we show that intracerebroventricular administration of minute amounts of leptin 
acutely ameliorates insulin resistance in ob/ob mice. Chronic calorie restriction, 
despite curtailing body weight to that of wild type controls, barely affects body 
composition of these animals. However, it does considerably blunt lipid accumulation 
in muscle and liver and also clearly reinforces insulin action on glucose production 
and disposal. As the mice were pair-fed for 3 days prior to the experimental 
procedures, we believe that the metabolic benefits we report here are primarily due 
to the constraint of adipose mass and tissue lipid storage, and not to calorie 
restriction per se. We infer that both leptin deficiency and the obese phenotype 
contribute to insulin resistance in ob/ob mice. Finally, circulating insulin levels during 
insulin infusion were consistently higher in ob/ob animals than in normal weight 
controls and i.c.v. leptin administration acutely reduced these levels, which suggests 
that leptin promotes (hepatic) insulin clearance via activation of cerebral leptin 
receptors. 
The current literature pertaining to the acute effects of leptin on glucose 
metabolism is rather confusing. Nevertheless, our finding that i.c.v. leptin 
administration acutely facilitates insulin action in ob/ob mice corroborates and 
complements various previous reports. Kamohara and coworkers were the first to 
show that both intravenous (i.v.) and i.c.v. leptin acutely enhance glucose turnover in 
wild-type C57/BL6 mice 10. Subsequently, Sivitz et al demonstrated, that i.v. leptin 
administration for 48 hours enhances the glucose infusion rate necessary to maintain 
euglycemia during insulin in normal weight Sprague Dawley rats 19. Rossetti et al 
reported that i.v. leptin for 6 hours enhances insulin's ability to inhibit endogenous 
glucose production, whereas it does not affect peripheral insulin action in lean 
Sprague-Dawley rats 20. They went on to show that i.c.v infusion of leptin redirects 
intrahepatic glucose flux, whereas it does not significantly impact on insulin's capacity 
to suppress HGP in these animals 21. In apparent contrast, Cusin et al. showed that 
subchronic (4 days) i.c.v. leptin treatment reinforces insulin action on glucose 
disposal, but not production, in lean heterozygous Zucker FA/fa rats 22. However, 
leptin treated animals had lost weight at the time hyperinsulinemic clamps were 
performed in their experiment, which probably explains the metabolic impact of the 
intervention as pair-fed animals, which were not treated with leptin, exhibited similar 
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metabolic features. We now demonstrate that i.c.v. leptin infusion acutely reinforces 
insulin action on glucose production and disposal in leptin deficient ob/ob mice. We 
believe that this model is ideally suitable for the study of acute metabolic effects of 
leptin, as exogenous leptin inevitably competes with endogenous peptide in other 
models. The mechanism that is responsible for the acute metabolic impact of i.c.v. 
leptin remains to be established. However, a single i.c.v. injection of leptin acutely 
activates AMPK in skeletal muscle of FVB mice 23 and downstream biochemical 
corollaries can stimulate glucose uptake 24. 
As far as we are aware, the impact of curtailing body weight by calorie 
restriction on insulin sensitivity has never been studied before in ob/ob mice. 
However, a wealth of data supports the position that calorie restriction prevents the 
onset of insulin resistance in various animal species 25, and weight loss promotes 
insulin action in humans (26 and references herein). The size of adipose depots, in 
particular the visceral fat mass, has an inverse correlation with insulin sensitivity, and 
the magnitude of beneficial change of insulin action in response to weight loss 
correlates with the percent decrease of visceral fat in humans 26. Moreover, (visceral) 
obesity is often accompanied by accumulation of lipids in tissues that are not 
designed to store triglycerides (i.e. muscle and liver) and this may impair insulin 
action in these tissues 27. Calorie restriction precluded lipid storage in liver and 
muscle to a large extent in our study. Thus, calorie restriction facilitates insulin action 
on glucose production and disposal in ob/ob mice, probably because it constrains the 
growth of adipose depots and largely prevents lipid storage in muscle and liver. 
Notably, all mice were pair-fed for 3 days prior to the experiments. Therefore, we 
believe that the metabolic benefits we report here are not due to calorie restriction 
per se. 
Our data showing that prolonged calorie restriction does not alter body 
composition (despite a reduction of body weight) corroborate previous reports 28-30. 
They strongly support the notion that leptin not just controls energy balance, but also 
directs fuel flux away from adipose tissue. In keeping with this, subchronic leptin 
administration specifically reduces (visceral) fat content in rats 4.  
Insulin clearance from the circulation may be controlled by leptin through activation of 
cerebral receptors. Ob/ob animals had consistently higher circulating insulin 
concentrations than wild-type controls during insulin infusion at an equal rate. This 
observation corroborates earlier papers, reporting that insulin clearance is reduced in 
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obese individuals 31. Insulin, when released by beta cells into the portal vein, is 
primarily cleared by the liver. The kidney is largely responsible for clearance of 
(exogenous) insulin from the systemic circulation 32. If insulin is not cleared by liver or 
kidney, basically all insulin sensitive tissues can internalize and degrade insulin, 
where muscle has a primary role 32. Elevated lipids and free fatty acids hamper 
insulin processing at the cellular and whole body level 33-35, perhaps through 
inhibition of insulin degrading enzyme 36. Thus, storage of excess TG in insulin 
degrading tissues (e.g. liver and kidney) may diminish insulin clearance in obesity 36. 
We were surprised to find that i.c.v. administration of leptin significantly reduced 
circulating insulin concentrations during continuous insulin infusion. This finding 
strongly suggests that leptin controls insulin clearance through activation of its 
receptors in the brain. 
What are the potential (patho)physiological implications of our findings? 
Growing evidence implies that obesity is a state of cerebral leptin resistance in many 
individuals 37. Disrupted leptin signal transduction in the brain may 1) produce obesity 
and favor accumulation of adipose tissue rather than lean body mass; 2) hamper 
insulin action to inhibit glucose production and stimulate glucose disposal; and 3) 
restrain insulin clearance. If so, drugs designed to impact signals downstream the 
leptin receptor conveying its metabolic messages (i.e. neuropeptide Y, pro-
opiomelanocortin 38) may be useful tools in the battle against obesity and type 2 
diabetes. 
In summary, we here show that leptin deficiency per se is deeply involved in 
the genesis of the metabolic phenotype of ob/ob mice. It is not just responsible for 
hyperphagia and obesity, but critically determines body composition, insulin action 
and insulin clearance from the circulation in these animals. The data suggest that 
putative cerebral leptin resistance in obese humans may underlie various features of 
the metabolic syndrome and therefore molecular messengers downstream the leptin 
receptor may be useful targets for the treatment of obesity and type 2 diabetes. 
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Obesity has now reached epidemic proportions globally and has become a worldwide 
public health problem. It can lead to several chronic diseases, including 
cardiovascular disease and type 2 diabetes mellitus. The problem of obesity arises 
when food intake exceeds energy expenditure. A complex system has evolved to 
regulate food intake and energy homeostasis, but this is biased towards weight gain. 
Several peripheral signals act within the central nervous system to give information 
about short-term and long-term energy stores. The integration of this multitude of 
signals occurs in the hypothalamus, which contains a large number of neuropeptides 
that influence food intake.  
The general hypothesis that is used throughout this thesis is, that the 
neuropeptides of this hypothalamic regulatory site of food intake and energy 
homeostasis are not only involved in regulation of food intake, but are also regulating 
insulin sensitivity, independently of the effects on food intake and body weight. 
Therefore, the aim of the studies described in this thesis was to investigate the 
effects of some of these neuropeptides and of some of the peripheral signals, which 
affect these neuropeptides, on insulin action. 
 All experiments described in this thesis were performed in mice. Usually wild-
type (C57BL\6) mice were used, except for chapter 6, in which ob/ob mice were used 
as well. Sometimes a high fat diet was used to induce insulin resistance. All 
experiments had a similar set-up consisting of administration of a certain 
hypothalamic neuropeptide or compound/hormone which can affect the hypothalamic 
regulatory center of food intake. Subsequently, insulin sensitivity was measured by a 
hyperinsulinemic euglycemic clamp technique. Mice were clamped in the fasted or 
fed state, depending on the (an)orexigenic nature of the administered 
neuropeptide/hormone. To ensure low physiological levels of the used 
neuropeptide/hormone, mice were clamped in the fed state for orexigenic agents and 
the fasted state for the anorexigenic agents. This way we could artificially raise the 
neuropeptide/hormone of our interest in the experimental group and evaluate the 
results against the low levels in the control group.  
Using this method, the effects of an icv infusion of the neuropeptide NPY on 
insulin sensitivity were studied in chapter 2. The results of this chapter show, that 
NPY can cause insulin resistance, specifically in the liver. Insulin-mediated glucose 
disposal was not affected by NPY, implying that organs like adipose tissue and 
muscle, were not affected.  
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The effect of the POMC pathway (the counter-regulating pathway of NPY) was 
studied in chapter 3 with the administration of MTII, an agonist of the POMC 
pathway. The results of that chapter show, that the POMC pathway can improve 
insulin-mediated glucose disposal and does not affect hepatic insulin sensitivity. 
Therefore, both pathways are not completely opposing each other’s effects, but seem 
to have a different tissue-specific effect.  
In chapters 4 and 5 the results on insulin sensitivity are shown for the acute 
(chapter 4) or chronic (chapter 5) administration of the gut hormone PYY. Both 
chapters show,  that PYY improves insulin sensitivity with respect to insulin mediated 
glucose disposal and there seems to be a tendency towards an improved hepatic 
insulin sensitivity as well.  
Finally, in chapter 6, the role of central leptin signalling on insulin sensitivity is 
examined in ob/ob mice and evaluated against the contribution of the obese 
phenotype itself on insulin sensitivity. The results show that both the obese 
phenotype and the lack of leptin signals in the brain, per se, contribute to the insulin 
resistance of ob/ob mice. 
 As mentioned before, the general hypothesis, that is used as the basis for the 
experiments described in this thesis, is that hypothalamic neuropeptides regulate 
insulin sensitivity, in addition to and independently of their role in regulating food 
intake. However, it is important to remember that other brain regions also play an 
important role in the regulation of food intake. Especially the brainstem, with the 
nucleus of the solitary tract in particular, but also parts of the limbic system, the 
amygdala and the cerebral cortex play a role 1. The results described in this thesis 
are in keeping with the hypothalamic model that we used, but it is important to keep 
in mind that they don’t prove the involvement of the hypothalamus. NPY, by example, 
is one of the most abundant neurotransmitters of the brain and its receptors are 
widely distributed throughout the brain 2. MTII, which is used in chapter 3, is an 
agonist of the MC 3 and 4 receptors. Although the MC3 receptor is mainly expressed 
in the hypothalamus, the MC4 receptor is expressed in virtually all major brain 
regions, including the brainstem 3. Similarly, the leptin receptor is also expressed in 
the brainstem 4. The icv infusion/injection that we used in our experiments could 
therefore affect parts of the brainstem as well, since the brainstem also has easy 
access to the csf via the fourth ventricle. Therefore, to evaluate the role of the 
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hypothalamus, additional experiments should be done with intra-hypothalamic 
injections. 
 The downstream mechanism via which the neuropeptides/hormones 
described in this thesis affect (insulin mediated) glucose turnover remains to be 
elucidated. First of all, the effects could be mediated via an endocrine mechanistic 
pathway. There are several hormones, like glucagon, growth hormone, 
corticosterone and epinephrine, which can affect glucose turnover 5-8. NPY and MTII, 
by example, have been shown to stimulate adrenocortical secretion via increased 
release of corticotrophin-releasing hormone (CRH) and adrenocorticotrophic 
hormone (ACTH) 9-11. NPY is also able to increase glucagon concentration 12. 
Although, we did not detect a modification of these hormones in our experimental 
settings (corticosterone and glucagon were measured in chapter 2 and 
corticosterone in chapter 3), the involvement of some of these hormones in the 
studies described in this thesis cannot be ruled out and could be a possible 
mechanism. Secondly, the effects could be mediated via a neural mechanistic 
pathway. Direct multisynaptic connections have been shown between the 
hypothalamus and peripheral organs that take up glucose, like liver, adipose tissue 
and muscle 13-17. Many studies show that parasympathetic input to these peripheral 
tissues is important for glucose uptake 15;17-20. Sympathetic neural activity in general 
stimulates hepatic glucose production 21-23. However, in addition to the sympathetic 
stimulation of hepatic glucose production, vagal input to the liver also modulates 
hepatic glucose production 24. Therefore, the effects on glucose turnover described in 
this thesis can also be mediated via a neural mechanistic pathway or perhaps a 
combination of neural and endocrine mechanistic pathways control glucose turnover. 
 When we compare the effects of the different neuropeptides/hormones 
described in this thesis, we observe that the NPY pathway causes hepatic insulin 
resistance, whereas the POMC pathway (MTII) improves peripheral insulin 
sensitivity. Furthermore, MTII was shown to stimulate basal glucose production. 
PYY3-36 and leptin are both known to inhibit the NPY- and stimulate the POMC 
pathway and would therefore be expected to improve insulin sensitivity. Indeed, 
PYY3-36 improved peripheral insulin sensitivity and had a small tendency to improve 
hepatic insulin sensitivity as well and leptin improved both hepatic and peripheral 
insulin sensitivity. However, MTII also affected basal glucose production, an effect 
that was not seen with PYY3-36 or leptin. This discrepancy can have several reasons. 
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First of all, we cannot rule out that some of the effects described in this thesis are not 
mediated via the hypothalamus but perhaps involve different brain regions, like the 
brain stem. The icv injections of MTII possibly affect the MC receptors in a more 
wide-spread brain area than the iv infusion of PYY3-36 does. Secondly, it could be a 
simple dose effect. In the studies described in this thesis a single dose was used 
(based on available literature that showed effects on food intake) and we therefore 
cannot rule out the possibility that we might see additional effects (including an effect 
on basal glucose production) if a higher dose was used. Finally, other neuropeptides, 
like AgRP and CART, could be involved as well. The effects of these neuropeptides 
on insulin sensitivity are barely investigated and they might be differentially affected 
by PYY3-36 and leptin. PYY3-36 and leptin might have an additional effect on these 
neuropeptides as well, as they are coexpressed with NPY and POMC neurons 
respectively. Currently, it is unknown how these neuropeptides affect insulin 
sensitivity. Therefore, the possibility exists that PYY3-36 and leptin additionally affect 
these neuropeptides, which can subsequently counteract the increase in basal 
glucose production that was caused by MTII. 
The experiments described in this thesis show the dual involvement of 
neuropeptides/hormones in the regulation of both food intake and insulin sensitivity. 
The physiological significance of this dual regulation could consist of an extra 
supplemental mechanism in the body’s attempt to maintain glucose homeostasis and 
a fine-tuning of this mechanism through the possibility of regulating insulin sensitivity 
in a tissue specific way. Hypothalamic NPY levels, by example, will be increased 
during fasting, which will lead to hepatic insulin resistance. This could be an 
additional mechanism to the low insulin levels that are present during the fasted 
state, ensuring that the hepatic glucose production will be maintained at a high level. 
The opposite pathway, the POMC pathway, will be increased in the fed state and will 
lead to an increased insulin sensitivity of peripheral tissues like muscle and adipose 
tissue. This will facilitate the glucose uptake by these tissues leading to an effective 
decrease in blood glucose levels. Leptin and PYY are both hormones that can 
influence both pathways. Leptin reflects the size of fat depots and therefore acts as a 
long-term regulator, while PYY is increased immediately after a meal and therefore 
acts as a short-term regulator that will decrease food intake and simultaneously 
increase insulin sensitivity to decrease blood glucose levels acutely.  
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 The central regulatory center for food intake and energy metabolism is 
extremely important in maintaining energy supply during times of plenty, but 
especially during times of famine. The experiments described in this thesis show that 
the neuropeptides and hormones that are involved in this regulation system, are not 
only involved in the regulation of food intake, but also in the regulation of insulin 
sensitivity. One could therefore hypothesize that disturbances in the regulation 
system itself, will lead to disturbances in both food intake and insulin sensitivity. 
Disturbances like leptin resistance and/or decreased PYY levels that were seen in 
obese subjects can therefore lead to a disturbed balance between the NPY and 
POMC pathway and can contribute to the increased food intake and insulin 
resistance. However, at present the role of these neuropeptides/hormones in the 
pathogeneses of obesity and type 2 diabetes in humans is still unknown.  
 
Implications for human pathophysiology 
Leptin was long thought of as the new therapeutic cure for obesity after successful 
experiments in several obese rodent models. However except for a few rare cases, 
obese humans turned out to be leptin resistant instead of leptin deficient. However, 
leptin resistance can eventually lead to the same metabolic consequences as leptin 
deficiency. We show in chapter 6 that leptin deficiency in ob/ob mice, particularly 
leptin deficiency in the brain, can lead to insulin resistance. For obese humans these 
findings imply that leptin resistance, particularly leptin resistance of the brain, can 
ultimately contribute to insulin resistance as well.  
For PYY3-36, human studies have shown that obese subject respond to PYY3-36 
by reduced food intake and are therefore not PYY3-36 resistant 25. Furthermore, it was 
shown that obese subjects have decreased PYY3-36 levels compared to lean 
subjects. For NPY and the POMC pathway, there are only a few studies that 
measured NPY or α-MSH levels in plasma or csf in obese and lean subjects.  
For NPY, some studies find higher NPY levels in obese subjects 26;27 and some 
studies find no differences 28;29. There is one study in which the distinction between 
obese non-diabetic and obese diabetic subjects was made and plasma NPY levels 
were found to be significantly higher in the diabetic subjects 30.  
For α-MSH, there are a few studies that find higher plasma levels in obese 
subjects and a negative correlation with insulin resistance 31;32. However, very little is 
known regarding the function of circulating α-MSH, as currently a great deal of 
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attention has focused on the central role of α-MSH and its antagonism at the MC4 
receptor by AgRP. There is one study that measured α-MSH in csf in obese and lean 
subjects, but no difference was found 28. However, the csf-concentrations do not 
reflect hypothalamic concentrations, as NPY and α-MSH are not only confined to the 
hypothalamic region. There is one study that examined the hypothalamic NPY 
protein in normal and obese subjects and they did not find any differences 33. 
However that study was based on four obese subjects only and did not make any 
distinction between insulin sensitive or insulin resistant subjects. Therefore, the 
possibility exists that obese and insulin resistant subjects, like mice susceptible to 
diet induced obesity, have increased hypothalamic NPY levels and decreased POMC 
levels, which could be of consequence in the pathogenesis of obesity and type 2 
diabetes mellitus. 
 Additional studies should be done that unravel the mechanism(s) by which the 
brain is capable of regulating insulin sensitivity. Both the endocrine or neural 
(sympathetic and parasympathetic) mechanistic pathways should be investigated. In 
addition, there are other neuropeptides and hormones that will play a role in the 
regulation of food intake and insulin sensitivity and these should be explored as well. 
It should be investigated in more detail whether disturbances in the balance of the 
NPY and POMC pathway or disturbances in other neuropeptides/hormones of this 
regulation system play a role in the pathogenesis of obesity or insulin resistance in 
humans. Furthermore, the possibility of (ant)agonists of these 
neuropeptides/hormones as a tool in the battle against obesity, type 2 diabetes and 
the metabolic syndrome should be investigated. There is still a lot of research that 
has to be done and several questions that still arise. The research described in this 
thesis is therefore a starting-point showing that neuropeptides/hormones that are 
involved in the regulation of food intake also, and independently of their effect on 




 1  Wilding JP. Neuropeptides and appetite control. Diabet.Med 2002; 19: 619-627. 
 2  Allen YS, Adrian TE, Allen JM et al. Neuropeptide Y distribution in the rat brain. Science 1983; 
221: 877-879. 
105
  General discussion 
  105 
 3  Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 
receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol.Endocrinol. 
1994; 8: 1298-1308. 
 4  Mercer JG, Moar KM, Hoggard N. Localization of leptin receptor (Ob-R) messenger ribonucleic 
acid in the rodent hindbrain. Endocrinology 1998; 139: 29-34. 
 5  Liljenquist JE, Chiassan JL, Cherrington AD et al. An important role for glucagon in the 
regulation of glucose production in vivo. Metabolism 1976; 25: 1371-1373. 
 6  Sacca L, Vigorito C, Cicala M, Corso G, Sherwin RS. Role of gluconeogenesis in epinephrine-
stimulated hepatic glucose production in humans. Am.J.Physiol 1983; 245: E294-E302. 
 7  Kahn CR, Goldfine ID, Neville DM, Jr., De Meyts P. Alterations in insulin binding induced by 
changes in vivo in the levels of glucocorticoids and growth hormone. Endocrinology 1978; 103: 
1054-1066. 
 8  Plaschke K, Muller D, Hoyer S. Effect of adrenalectomy and corticosterone substitution on 
glucose and glycogen metabolism in rat brain. J.Neural Transm. 1996; 103: 89-100. 
 9  Lu XY, Barsh GS, Akil H, Watson SJ. Interaction between alpha-melanocyte-stimulating 
hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-
pituitary-adrenal responses. J.Neurosci. 2003; 23: 7863-7872. 
 10  Hanson ES, Dallman MF. Neuropeptide Y (NPY) may integrate responses of hypothalamic 
feeding systems and the hypothalamo-pituitary-adrenal axis. J.Neuroendocrinol. 1995; 7: 273-
279. 
 11  Wahlestedt C, Skagerberg G, Ekman R, Heilig M, Sundler F, Hakanson R. Neuropeptide Y 
(NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-
adrenocortical axis in the rat. Brain Res. 1987; 417: 33-38. 
 12  Marks JL, Waite K. Some acute effects of intracerebroventricular neuropeptide Y on insulin 
secretion and glucose metabolism in the rat. J Neuroendocrinol 1996; 8: 507-513. 
 13  la Fleur SE, Kalsbeek A, Wortel J, Buijs RM. Polysynaptic neural pathways between the 
hypothalamus, including the suprachiasmatic nucleus, and the liver. Brain Res. 2000; 871: 50-
56. 
 14  Bamshad M, Aoki VT, Adkison MG, Warren WS, Bartness TJ. Central nervous system origins of 
the sympathetic nervous system outflow to white adipose tissue. Am.J.Physiol 1998; 275: R291-
R299. 
 15  Kreier F, Fliers E, Voshol PJ et al. Selective parasympathetic innervation of subcutaneous and 
intra-abdominal fat--functional implications. J.Clin.Invest 2002; 110: 1243-1250. 
 16  Burant CF, Lemmon SK, Treutelaar MK, Buse MG. Insulin resistance of denervated rat muscle: 
a model for impaired receptor-function coupling. Am.J.Physiol 1984; 247: E657-E666. 
 17  Lang CH, Ajmal M, Baillie AG. Neural control of glucose uptake by skeletal muscle after central 
administration of NMDA. Am.J.Physiol 1995; 268: R492-R497. 
 18  Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab 
Rev. 1987; 3: 185-206. 
 19  Niijima A. Nervous regulation of metabolism. Prog.Neurobiol. 1989; 33: 135-147. 
 20  Moore MC, Satake S, Baranowski B, Hsieh PS, Neal DW, Cherrington AD. Effect of hepatic 
denervation on peripheral insulin sensitivity in conscious dogs. Am.J.Physiol Endocrinol.Metab 
2002; 282: E286-E296. 
106
Chapter 7   
106 
 21  Shimazu T, Amakawa A. Regulation of glycogen metabolism in liver by the autonomic nervous 
system. 3. Differential effects of sympathetic-nerve stimulation and of catecholamines on liver 
phosphorylase. Biochim.Biophys.Acta 1968; 165: 349-356. 
 22  Pascoe WS, Smythe GA, Storlien LH. 2-deoxy-D-glucose-induced hyperglycemia: role for direct 
sympathetic nervous system activation of liver glucose output. Brain Res. 1989; 505: 23-28. 
 23  Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. 
Diabetologia 2000; 43: 533-549. 
 24  Cardin S, Walmsley K, Neal DW, Williams PE, Cherrington AD. Involvement of the vagus nerves 
in the regulation of basal hepatic glucose production in conscious dogs. Am.J.Physiol 
Endocrinol.Metab 2002; 283: E958-E964. 
 25  Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide 
YY3-36. N.Engl.J.Med 2003; 349: 941-948. 
 26  Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed 
release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes.Metab 
2000; 2: 99-103. 
 27  Baranowska B, Wasilewska-Dziubinska E, Radzikowska M, Plonowski A, Roguski K. 
Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia 
nervosa. Metabolism 1997; 46: 1384-1389. 
 28  Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, Marcus C. Cerebrospinal fluid and plasma 
concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to 
negative energy balance. J.Clin.Endocrinol.Metab 2001; 86: 4849-4853. 
 29  Brunani A, Invitti C, Dubini A et al. Cerebrospinal fluid and plasma concentrations of SRIH, beta-
endorphin, CRH, NPY and GHRH in obese and normal weight subjects. Int.J.Obes.Relat Metab 
Disord. 1995; 19: 17-21. 
 30  Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y 
and leptin levels in obese women with and without type 2 diabetes mellitus. Int.J.Obes.Relat 
Metab Disord. 2000; 24 Suppl 2: S152-S153. 
 31  Katsuki A, Sumida Y, Murashima S et al. Elevated plasma levels of alpha-melanocyte 
stimulating hormone (alpha-MSH) are correlated with insulin resistance in obese men. 
Int.J.Obes.Relat Metab Disord. 2000; 24: 1260-1264. 
 32  Hoggard N, Johnstone AM, Faber P et al. Plasma concentrations of alpha-MSH, AgRP and 
leptin in lean and obese men and their relationship to differing states of energy balance 
perturbation. Clin.Endocrinol.(Oxf) 2004; 61: 31-39. 
 33  Goldstone AP, Unmehopa UA, Bloom SR, Swaab DF. Hypothalamic NPY and agouti-related 
protein are increased in human illness but not in Prader-Willi syndrome and other obese 











Summary / Samenvatting 
108
Summary / Samenvatting   
108 
109
  Summary / Samenvatting 
  109 
Summary 
Nowadays, in our Western society food is in abundance and energy-rich with high 
levels of sugar and saturated fats. At the same time, large shifts towards less 
physically demanding work have been observed. These environmental changes are 
reflected in the large number of overweight/obese people. Obesity has now reached 
epidemic proportions globally and has become a worldwide public health problem. It 
can lead to several chronic diseases, including cardiovascular disease and insulin 
resistance/type 2 diabetes mellitus. The problem of obesity arises when food intake 
exceeds energy expenditure.  
 Food intake or energy intake is regulated by a highly complex system, that 
integrates several signals concerning the metabolic status and energy expenditure. 
This regulation mechanism consists of several central regulation centers, which are 
situated in several different brain regions, particularly in the hypothalamus, which is 
considered as the main feeding center of the brain. In the hypothalamus there are 
two opposing pathways that regulate food intake: one pathway stimulates food intake 
and consists of neurons, that produce the neuropeptides NPY (neuropeptide Y) 
and/or AgRP (agouti-related peptide), the other pathway inhibits food intake and 
consists of neurons that produce the neuropeptides POMC (pro-opiomelanocortin) 
and/or CART (cocaine- and amphetamine-regulated transcript). 
 In addition to these central regulation centers of food intake, there are 
numerous peripheral signals, which are also involved in the regulation of food intake. 
These factors are derived from different organs like stomach, gut, pancreas and 
adipose tissue, by example. These hormones act on the central regulation centers, 
and, thereby, contribute to the regulation of food intake by providing the brain 
information about hunger, satiety and body fat stores. 
 The hypothesis, that is used throughout this thesis, is that the 
neuropeptides/hormones that are involved in the regulation of food intake, also 
regulate insulin sensitivity (besides and independent of their role in regulating food 
intake). In obesity, dysregulation of several hypothalamic neuropeptides and 
peripheral hormones that regulate food intake, has been observed and will lead to an 
increased food intake. Perhaps the same dysregulation of these neuropeptides and 
hormones can cause insulin resistance as well. 
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In chapter 2 the effects of NPY, the most important neuropeptide of the 
pathway that stimulates food intake, on insulin sensitivity were studied, independent 
of the effects on food intake or body weight. NPY was continuously infused in the 
lateral ventricle of the brain (icv) of mice and insulin sensitivity was simultaneously 
determined by means of a hyperinsulinemic euglycemic clamp technique. The results 
of this chapter show increased hepatic glucose and VLDL production under 
hyperinsulinemic conditions, and thereby provide evidence, that icv NPY 
administration precludes the inhibition of hepatic glucose and VLDL production by 
circulating insulin. This finding may imply, that the increased hypothalamic NPY 
levels, that are typically observed in various obese animal models may underlie 
hepatic insulin resistance and associated metabolic anomalies in these models. 
The aim of chapter 3 was to evaluate the effects of central administration of 
melanotan II (MTII), on hepatic and whole-body insulin sensitivity, independent of 
food intake and body weight. MTII is an agonist of the melanocortin receptors 3 and 
4, which are both receptors of the POMC pathway, the pathway that inhibits food 
intake. The results of this chapter show an increase in the basal glucose production 
and uptake after central administration of MTII. Furthermore, hyperinsulinemic 
glucose uptake was increased in the mice that received MTII, whereas the inhibitory 
effect of insulin on hepatic glucose production was not affected by MTII. We, 
therefore, conclude, that icv administration of MTII acutely increases insulin-mediated 
glucose disposal, but does not affect insulins capacity to suppress the hepatic 
glucose production in mice. These data indicate, that central stimulation of 
melanocortin-3/4 receptors modulates insulin sensitivity in a tissue-specific manner, 
independent of its well-known impact on feeding and body weight.  
In chapter 4, the acute effects of PYY3-36 on insulin sensitivity were 
investigated. PYY3-36 is a hormone, that is released by the gut in response to nutrient 
ingestion. It modulates the activities of orexigenic NPY neurons and anorexigenic 
POMC neurons in the hypothalamus to inhibit food intake. As both NPY and POMC 
have been shown to also impact insulin action, we wondered whether PYY3-36 could 
improve insulin sensitivity. PYY3-36 was therefore intravenously infused in mice during 
a hyperinsulinemic euglycemic clamp. The results of this chapter show, that in 
hyperinsulinemic conditions, glucose disposal was significantly increased in PYY3-36-
infused- compared with vehicle-infused mice. We therefore conclude, that PYY3-36 
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improves insulin sensitivity, in particular the ability of insulin to enhance glucose 
disposal. 
Because the long-term effects of PYY3-36 on insulin sensitivity are still 
unknown, the effects of chronic PYY3-36 administration on insulin sensitivity were 
examined in chapter 5. In addition, metabolic efficacy of continuous vs. intermittent 
administration of PYY3-36 was evaluated. Mice therefore received PYY3-36 
subcutaneously for 7 days by means of an osmotic minipump or daily subcutaneous 
injections, after which insulin sensitivity was determined with the hyperinsulinemic 
euglycemic clamp technique. In hyperinsulinemic conditions, glucose disposal was 
significantly increased in PYY3-36 treated mice vs. vehicle-treated mice. In contrast, 
insulin action on hepatic glucose production was not significantly affected, although 
there was a tendency towards enhanced ability of insulin to suppress hepatic glucose 
production. Furthermore, none of these metabolic parameters was affected by the 
mode of PYY3-36 administration (continuous or intermittent). These observations 
suggest, that PYY3-36 or potential analogues may be a useful treatment for insulin 
resistance. 
 Finally, in chapter 6, the role of the adipose tissue-derived hormone leptin and 
the role of its central signalling on insulin sensitivity is examined in ob/ob mice and 
evaluated against the contribution of the obese phenotype itself on insulin sensitivity. 
To explore the contribution of cerebral leptin deficiency to insulin resistance in leptin 
deficient ob/ob mice, we infused leptin icv in ob/ob mice. To also evaluate the impact 
of adiposity on insulin action in these animals, another group of young ob/ob animals 
were subjected to severe calorie restriction, so that their body weight became similar 
to that of wild type mice. The hyperinsulinemic euglycemic clamp technique was 
subsequently used to determine insulin sensitivity. Icv leptin infusion acutely 
increased both the hepatic insulin sensitivity and insulin-mediated glucose disposal in 
ob/ob mice. Furthermore, icv leptin administration acutely reduced circulating insulin 
levels during continuous insulin infusion (hyperinsulinemic period). Food restriction 
barely affected body composition although it profoundly curtailed body weight. Insulin 
suppressed the hepatic glucose production clearly more in the lean ob/ob mice than 
in their obese counterparts, but its impact remained less than in wild-type mice. 
Insulin-mediated glucose disposal of lean ob/ob mice was also in between that of 
obese ob/ob and lean wild-types. In conclusion, leptin deficiency per se is not just 
responsible for hyperphagia and obesity in ob/ob mice, but critically determines body 
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composition, insulin action and insulin clearance from the circulation in these 
animals. The data suggest that leptin resistance in obese humans may contribute to 
insulin resistance and hyperinsulinemia in these individuals. 
 
In conclusion, the studies presented in this thesis show the effects of several 
neuropeptides/hormones on insulin sensitivity. As there is still a lot of research that 
has to be done, the research described in this thesis can be considered as a starting-
point showing that neuropeptides/hormones that are involved in the regulation of food 
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Samenvatting 
Tegenwoordig is in onze Westerse samenleving voedsel in overvloed aanwezig en 
bovendien energierijk, met hoge suikergehaltes en veel verzadigde vetten. 
Tegelijkertijd worden er enorme verschuivingen waargenomen naar fysiek minder 
veeleisend werk. Deze veranderingen in onze omgeving worden gereflecteerd in het 
percentage mensen dat kampt met overgewicht/obesitas. Obesitas heeft inmiddels 
globaal gezien epidemische proporties aangenomen en is een wereldwijd 
gezondheidsprobleem geworden. Het kan tot verschillende chronische ziekten 
leiden, waaronder cardiovasculaire aandoeningen en insuline resistentie/type 2 
diabetes mellitus. Het probleem van obesitas ontstaat op het moment dat de 
voedselinname het energieverbruik overschrijdt. 
 Voedselinname of energie-inname wordt gereguleerd door een complex 
systeem dat de verschillende signalen omtrent de metabole status en het 
energieverbruik integreert. Dit regulatiesysteem bestaat uit verschillende centrale 
regulatiecentra die gesitueerd zijn in verschillende hersengebieden, met name in de 
hypothalamus, het gebied dat wordt beschouwd als het belangrijkste 
voedingscentrum van de hersenen. In de hypothalamus zijn er twee 
tegenovergestelde paden die voedselinname reguleren: één pad stimuleert 
voedselinname en bestaat uit neuronen die de neuropeptiden NPY (neuropeptide Y) 
en/of AgRP (agouti-gerelateerd peptide) produceren, het andere pad inhibeert 
voedselinname en bestaat uit neuronen die de neuropeptiden POMC (pro-
opiomelanocortine) en/of CART (cocaïne- en amfetamine gereguleerd transcript). 
 Naast deze centrale regulatiecentra van voedselinname, zijn er ook veel 
perifere signalen die ook betrokken zijn bij de regulatie van voedselinname. Deze 
factoren komen vanuit verschillende organen zoals maag, darm, pancreas en 
vetweefsel, bijvoorbeeld. Deze hormonen werken op de centrale regulatiecentra en 
dragen daarmee bij aan de regulatie van voedselinname door de hersenen te 
voorzien van informatie betreffende honger, verzadiging en vet-voorraden. 
 De hypothese, waarop de studies uit dit proefschrift gebaseerd zijn, is dat de 
neuropeptiden/hormonen die betrokken zijn bij de regulatie van voedselinname, ook 
de insulinegevoeligheid reguleren (naast en onafhankelijk van hun rol in de regulatie 
van voedselinname). Bij obesitas is er een disregulatie waargenomen van 
verschillende hypothalame neuropeptiden en perifere hormonen die voedselinname 
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reguleren. Wellicht kan dezelfde disregulatie van deze neuropeptiden en hormonen 
ook insulineresistentie veroorzaken. 
 In hoofdstuk 2 werden de effecten van NPY, het belangrijkste neuropeptide 
van het pad dat voedselinname stimuleert, op insulinegevoeligheid onderzocht, 
onafhankelijk van de effecten op voedselinname of lichaamsgewicht. NPY werd 
continu geïnfuseerd in het laterale ventrikel van de hersenen (icv) van muizen en de 
insulinegevoeligheid werd tegelijkertijd bepaald met behulp van de 
hyperinsulinemische euglycemische clamp techniek. De resultaten van dat hoofdstuk 
laten onder hyperinsulinemische condities een verhoogde hepatische glucose- en 
VLDL-produktie zien en tonen daarmee aan, dat icv NPY toediening de inhibitie van 
de hepatische glucose- en VLDL-produktie door insuline kan voorkomen. Deze 
bevinding impliceert, dat de toegenomen hypothalame NPY levels, die worden 
waargenomen in verschillende obese diermodellen, wellicht ten grondslag liggen aan 
de hepatische insulineresistentie en de daarmee geassocieerde metabole 
afwijkingen van deze modellen. 
 Het doel van hoofdstuk 3 was om de effecten van centrale toediening van 
melanotan II (MTII), op hepatische en totale insulinegevoeligheid te onderzoeken, 
onafhankelijk van voedselinname en lichaamsgewicht. MTII is een agonist van de 
melanocortine receptoren 3 en 4, dat beiden receptoren zijn van de POMC route, 
welke voedselinname inhibeert. De resultaten van dat hoofdstuk laten een toename 
zien in de basale glucose produktie en opname na centrale toediening van MTII. 
Bovendien was de hyperinsulinemische glucose opname toegenomen in de muizen 
die MTII hadden ontvangen, terwijl MTII geen effect had op het inhiberende effect 
van insuline op de hepatische glucose produktie. We concluderen hieruit, dat icv 
toediening van MTII acuut de insuline-gemedieerde glucose opname verhoogt, maar 
geen effect heeft op het vermogen van insuline om de hepatische glucose produktie 
te onderdrukken. Deze data geven aan, dat centrale stimulatie van de melanocortine 
3/4 receptoren de insulinegevoeligheid moduleert op een weefselspecifieke manier 
en onafhankelijk van het al bekende effect op voedselinname en lichaamsgewicht. 
 In hoofdstuk 4 werden de acute effecten van PYY3-36 op insulinegevoeligheid 
onderzocht. PYY3-36 is een hormoon, dat wordt afgescheiden door de darm in 
respons op een maaltijd. Het moduleert de activiteiten van de orexigene NPY 
neuronen en de anorexigene POMC neuronen in de hypothalamus om zo 
voedselinname te inhiberen. Aangezien zowel NPY als POMC een effect heeft op de 
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insulinewerking, vroegen wij ons af of PYY3-36 de insulinegevoeligheid zou kunnen 
verbeteren. PYY3-36 werd daarom intraveneus geïnfuseerd bij muizen tijdens een 
hyperinsulinemische euglycemische clamp. De resultaten van dat hoofdstuk laten 
zien dat onder hyperinsulinemische condities, de glucose opname significant is 
toegenomen in PYY-geïnfuseerde dieren in vergelijking met vehicle-geïnfuseerde 
muizen. We concluderen hieruit, dat PYY3-36 de insulinegevoeligheid verbetert, met 
name het vermogen van insuline om de glucose opname te stimuleren. 
 Aangezien de lange-termijn effecten van PYY3-36 op insulinegevoeligheid nog 
onbekend zijn, werden de effecten van chronische PYY3-36 toediening op 
insulinegevoeligheid onderzocht in hoofdstuk 5. Daarnaast werd ook de metabole 
efficiëntie van continue vs. onderbroken toediening van PYY3-36 onderzocht. Muizen 
kregen daarvoor 7 dagen lang subcutaan PYY3-36 toegediend dmv een osmotische 
minipomp die onderhuids werd geplaatst of dmv dagelijkse subcutane injecties, 
waarna vervolgens de insulinegevoeligheid werd gemeten met de 
hyperinsulinemische euglycemische clamp techniek. Onder hyperinsulinemische 
condities was de glucose opname significant toegenomen in de PYY-behandelde 
dieren vs. vehicle-behandelde dieren. De insulinewerking op de hepatische glucose 
produktie was daarentegen niet significant veranderd, alhoewel er een tendens was 
tot een toegenomen vermogen van insuline om de hepatische glucose produktie te 
onderdrukken. Bovendien werd geen van deze metabole parameters beïnvloed door 
de wijze van PYY3-36 toediening (continu of onderbroken). Deze observaties 
suggereren dat PYY3-36 of potentiele analogen een nuttige behandeling kunnen 
vormen tegen insulineresistentie. 
 Ten slotte werd in hoofdstuk 6 de rol van het door vetweefsel geproduceerde 
hormoon leptine en de rol van de centrale signalling hiervan op insulinegevoeligheid 
onderzocht in ob/ob (leptine deficiente) muizen en afgezet tegen de bijdrage van het 
obese fenotype zelf op insulinegevoeligheid. Om de bijdrage van cerebrale leptine 
deficientie op insulineresistentie te onderzoeken, werd leptine icv geïnfuseerd in 
ob/ob muizen. Om ook de impact van de hoeveelheid vet op de insuline werking te 
onderzoeken, werd een andere groep jonge ob/ob muizen op strenge calorie 
restrictie gezet, zodat hun lichaamsgewicht gelijk werd aan dat van de wild-type 
muizen. De hyperinsulinemische euglycemische clamp techniek werd vervolgens 
gebruikt om de insulinegevoeligheid te bepalen. Icv leptine infusie verhoogde acuut 
zowel de hepatische insulinegevoeligheid als de insuline gemedieerde glucose 
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opname. Bovendien reduceerde icv leptine acuut de circulerende insuline 
concentraties gedurende continue insuline infusie (hyperinsulinemische periode). 
Voedselrestrictie had nauwelijks invloed op de lichaamssamenstelling ondanks de 
aanzienlijke vermindering van lichaamsgewicht. Insuline onderdrukte de hepatische 
glucose produktie duidelijk meer in de dunne ob/ob muizen in vergelijking met de 
dikke ob/ob muizen, maar dit effect bleef verminderd in vergelijking met de wild-type 
muizen. Insuline-gemedieerde glucose opname van de dunne ob/ob muizen lag ook 
in tussen die van de obese ob/ob en de dunne wild-type muizen. We concluderen 
hieruit dat leptine deficientie per se niet slechts verantwoordelijk is voor de 
hyperfagie en obesitas in ob/ob muizen, maar bepalend is voor 
lichaamssamenstelling, insulinewerking en insulineklaring vanuit de circulatie in deze 
dieren. De data suggereert dat leptineresistentie in obese patienten mogelijk bij kan 
dragen aan de insulineresistentie en hyperinsulinemie van deze individuen. 
 
Concluderend, de studies in dit proefschrift laten de effecten zien van verschillende 
neuropeptiden/hormonen op insulinegevoeligheid. Aangezien er nog veel onderzoek 
gedaan moet worden hieraan, kan het hier beschreven onderzoek beschouwd 
worden als een beginpunt dat laat zien, dat neuropeptiden/hormonen die betrokken 
zijn bij de regulatie van voedselinname ook, en onafhankelijk van hun effect op 
voedselinname, insulinegevoeligheid beïnvloeden. 
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